RTI Surgical (RTIX) 10-K10 Mar 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Jun. 30, 2013	Feb. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'RTI SURGICAL, INC.	'	'
Entity Central Index Key	'0001100441	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	'	56,602,063
Entity Public Float	'	$211.80	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current Assets:	'	'
Cash and cash equivalents	$18,721	$49,696
Accounts receivable-less allowances of $492 at December 31, 2013 and $346 at December 31, 2012	31,752	21,694
Inventories-net	106,126	76,509
Prepaid and other current assets	5,483	6,075
Deferred tax assets-net	24,577	12,598
Total current assets	186,659	166,572
Property, plant and equipment-net	74,738	49,644
Deferred tax assets-net	5,452	8,652
Goodwill	54,887	2,062
Other intangible assets-net	33,786	13,766
Other assets-net	14,332	713
Total assets	369,854	241,409
Current Liabilities:	'	'
Accounts payable	23,231	11,949
Accrued expenses	22,478	20,594
Deferred tax liabilities	195	'
Current portion of deferred revenue	5,109	4,803
Current portion of short and long-term obligations	1,344	116
Total current liabilities	52,357	37,462
Long-term obligations-less current portion	67,706	4
Other long-term liabilities	13,446	698
Deferred tax liabilities	'	473
Deferred revenue	18,755	18,780
Total liabilities	152,264	57,417
Preferred stock Series A, $.001 par value: 5,000,000 shares authorized; 50,000 shares issued and outstanding at December 31, 2013	49,537	'
Stockholders' equity:	'	'
Common stock, $.001 par value: 150,000,000 shares authorized; 56,388,063 and 55,985,394 shares issued and outstanding, respectively	56	56
Additional paid-in capital	415,426	414,482
Accumulated other comprehensive loss	-812	-1,776
Accumulated deficit	-246,550	-228,736
Less treasury stock, 146,957 and 138,297 shares, at cost	-67	-34
Total stockholders' equity	168,053	183,992
Total liabilities and stockholders' equity	$369,854	$241,409

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, allowances	$492	$346
Preferred stock, par value	$0.00	'
Preferred stock, shares authorized	5,000,000	'
Preferred stock, shares issued	50,000	'
Preferred stock, shares outstanding	50,000	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	56,388,063	56,388,063
Common stock, shares outstanding	55,985,394	55,985,394
Treasury stock, shares	146,957	138,297

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive (Loss) Income (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Revenues	$197,979	$178,113	$169,316
Costs of processing and distribution	117,874	92,896	92,102
Gross profit	80,105	85,217	77,214
Expenses:	'	'	'
Marketing, general and administrative	81,635	58,376	55,576
Research and development	15,241	12,231	9,806
Asset abandonments	'	20	61
Litigation settlement	3,000	2,350	'
Restructuring charges	2,881	'	'
Acquisition expenses	6,004	'	'
Total operating expenses	108,761	72,977	65,443
Operating (loss) income	-28,656	12,240	11,771
Other (expense) income:	'	'	'
Interest expense	-542	'	-201
Interest income	23	185	193
Foreign exchange gain (loss)	251	19	-159
Total other (expense) income-net	-268	204	-167
(Loss) income before income tax benefit (provision)	-28,924	12,444	11,604
Income tax benefit (provision)	11,110	-4,042	-3,226
Net (loss) income	-17,814	8,402	8,378
Convertible preferred dividend	-1,375	'	'
Net (loss) income applicable to common shares	-19,189	8,402	8,378
Other comprehensive (loss) income:	'	'	'
Unrealized foreign currency translation gain (loss)	964	408	-746
Comprehensive (loss) income	($18,225)	$8,810	$7,632
Net (loss) income per common share-basic	($0.34)	$0.15	$0.15
Net (loss) income per common share-diluted	($0.34)	$0.15	$0.15
Weighted average shares outstanding-basic	56,258,624	55,861,957	55,150,886
Weighted average shares outstanding-diluted	56,258,624	56,068,795	55,354,675

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Treasury Stock [Member]
In Thousands	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Series A Preferred Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Series A Preferred Stock [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]	Treasury Stock [Member]	Series A Preferred Stock [Member]
Beginning Balance at Dec. 31, 2010	$161,936	'	$55	$408,849	'	($1,438)	'	($245,516)	'	($14)	'
Net (loss) income	8,378	'	'	'	'	'	'	8,378	'	'	'
Foreign currency translation adjustment	-746	'	'	'	'	-746	'	'	'	'	'
Exercise of common stock options	1,122	'	1	1,121	'	'	'	'	'	'	'
Stock-based compensation	1,973	'	'	1,973	'	'	'	'	'	'	'
Change in income tax benefit from stock-based compensation	-244	'	'	-244	'	'	'	'	'	'	'
Ending Balance at Dec. 31, 2011	172,419	'	56	411,699	'	-2,184	'	-237,138	'	-14	'
Net (loss) income	8,402	'	'	'	'	'	'	8,402	'	'	'
Foreign currency translation adjustment	408	'	'	'	'	408	'	'	'	'	'
Exercise of common stock options	514	'	'	514	'	'	'	'	'	'	'
Stock-based compensation	2,078	'	'	2,078	'	'	'	'	'	'	'
Purchase of treasury stock	-20	'	'	'	'	'	'	'	'	-20	'
Amortization of preferred stock Series A issuance costs	'	'	'	'	'	'	'	'	'	'	'
Change in income tax benefit from stock-based compensation	191	'	'	191	'	'	'	'	'	'	'
Ending Balance at Dec. 31, 2012	183,992	'	56	414,482	'	-1,776	'	-228,736	'	-34	'
Net (loss) income	-17,814	'	'	'	'	'	'	-17,814	'	'	'
Foreign currency translation adjustment	964	'	'	'	'	964	'	'	'	'	'
Exercise of common stock options	332	'	'	332	'	'	'	'	'	'	'
Stock-based compensation	2,220	'	'	2,220	'	'	'	'	'	'	'
Purchase of treasury stock	-33	'	'	'	'	'	'	'	'	-33	'
Amortization of preferred stock Series A issuance costs	-77	-77	'	'	-77	'	'	'	'	'	'
Preferred stock Series A dividend	'	-1,375	'	'	-1,375	'	'	'	'	'	'
Change in income tax benefit from stock-based compensation	-156	'	'	-156	'	'	'	'	'	'	'
Ending Balance at Dec. 31, 2013	$168,053	'	$56	$415,426	'	($812)	'	($246,550)	'	($67)	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net (loss) income	($17,814)	$8,402	$8,378
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:	'	'	'
Depreciation and amortization expense	12,202	7,993	8,026
Provision for bad debts and product returns	435	136	450
Provision for inventory write-downs	1,785	3,114	4,840
Amortization of deferred revenue	-6,451	-4,656	-4,353
Deferred income tax (benefit) provision	-11,544	797	-1,584
Stock-based compensation	2,220	2,078	1,973
Other	227	706	114
Change in assets and liabilities:	'	'	'
Accounts receivable	-50	-1,121	-1,054
Inventories	5,231	-2,880	5,558
Accounts payable	5,276	3,527	-2,564
Accrued expenses	-3,247	1,002	5,353
Deferred revenue	6,000	3,000	'
Other operating assets and liabilities	1,276	-1,295	2,630
Net cash (used in) provided by operating activities	-4,454	20,803	27,767
Cash flows from investing activities:	'	'	'
Purchases of property, plant and equipment	-15,011	-11,089	-6,345
Patent and acquired intangible asset costs	-915	-3,772	-2,139
Acquisition of Pioneer Surgical Technology	-126,307	'	'
Acquisition of recovery agency assets	'	-3,000	'
Other investing activities	'	49	'
Net cash used in investing activities	-142,233	-17,812	-8,484
Cash flows from financing activities:	'	'	'
Proceeds from exercise of common stock options	332	514	1,122
Proceeds from long-term obligations	68,250	'	'
Net proceeds from short-term obligations	638	'	'
Payment of debt issuance costs	-699	'	'
Proceeds from preferred stock issuance	50,000	'	'
Payment of preferred stock issuance costs	-1,290	'	'
Payment of preferred stock dividend	-625	'	'
Payments on long-term obligations	-142	-471	-2,600
Other financing activities	-841	474	282
Net cash provided by (used in) financing activities	115,623	517	-1,196
Effect of exchange rate changes on cash and cash equivalents	89	10	-121
Net (decrease) increase in cash and cash equivalents	-30,975	3,518	17,966
Cash and cash equivalents, beginning of period	49,696	46,178	28,212
Cash and cash equivalents, end of period	18,721	49,696	46,178
Supplemental cash flow disclosure:	'	'	'
Cash paid for interest	570	22	128
Cash paid for income taxes, net of refunds	2,819	3,187	410
Change in accrual for purchases of property, plant and equipment	1,557	199	1,056
Change in accrual for acquired intangible asset costs	'	1,690	2,109
Contingent consideration for asset purchase	'	$900	'

Business

Business	12 Months Ended
Business	Dec. 31, 2013
Accounting Policies [Abstract]	'
Business	'
	1. Business
	RTI Surgical, Inc. (the “Company”), and its subsidiaries recover and process human and animal tissue and manufacture metal and synthetic implants and instruments. The processing transforms the tissue into either conventional or precision machined allograft implants (human) or xenograft implants (animal). The implants are used for orthopedic and other surgical applications to promote the natural healing of human bone and other human tissue. These implants are distributed domestically and internationally, for use in reconstruction and fracture repair.

Summary_of_Significant_Account

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation—The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Pioneer Surgical Technology, Inc. (“Pioneer”), Tutogen Medical, Inc. (“TMI”), RTI Biologics, Inc. – Cardiovascular (inactive), Biological Recovery Group (inactive), and RTI Services, Inc. The consolidated financial statements also include the accounts of RTI Donor Services, Inc. (“RTIDS”), which is a controlled entity. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.

RTIDS is a taxable not-for-profit entity organized and controlled by the Company. RTIDS is the corporate entity that is responsible for procuring tissue for the Company. Expenses incurred by RTIDS to procure tissue are passed through to the Company. RTIDS has no significant assets or liabilities except for its intercompany accounts receivable and accounts payable to tissue recovery agencies. The Company pays all expenses of RTIDS.

Use of Estimates—The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions relating to inventories, receivables, long-lived assets, investment valuations and litigation are made at the end of each financial reporting period by management. Actual results could differ from those estimates.

Foreign Currency Translation—The functional currency of the Company’s foreign subsidiaries is the Euro. Assets and liabilities of the foreign subsidiaries are translated at the period end exchange rate while revenues and expenses are translated at the average exchange rate for the period. The resulting translation adjustments, representing unrealized, noncash gains and losses are recorded and presented as a component of comprehensive income (loss). Gains and losses resulting from transactions of the Company and its subsidiaries, which are made in currencies different from their own, are included in income or loss as they occur and are included in net other income (expense) in the consolidated statements of comprehensive income (loss).

Fair Value of Financial Instruments—The estimated fair value of financial instruments disclosed in the consolidated financial statements has been determined by using available market information and appropriate valuation methodologies. The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The carrying value of the long-term debt obligations approximates fair value. The carrying value of capital lease obligations approximates the fair value, based on current market prices.

Presentation of Comprehensive Income (Loss)—In June 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-05, Comprehensive Income (Loss) (Topic 220) – Presentation of Comprehensive Income (Loss) (ASU 2011-05), to require an entity to present the total of comprehensive income (loss), the components of net income (loss), and the components of other comprehensive income (loss) either in a single continuous statement of comprehensive income or in two separate but consecutive statements. ASU 2011-05 eliminates the option to present the components of other comprehensive income (loss) as part of the statement of equity. ASU 2011-05 was effective in the first quarter of 2012 and was applied retrospectively. Accumulated other comprehensive income (loss) includes cumulative foreign currency translation adjustments.

Cash and Cash Equivalents—The Company considers all funds in banks and short-term highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. Cash equivalents comprise overnight repurchase agreements. Cash balances are held at a few financial institutions and usually exceed insurable amounts. The Company mitigates this risk by depositing its uninsured cash in major well capitalized financial institutions, and by investing excess operating cash in overnight repurchase agreements which are 101% collateralized by U.S. Government backed securities with the Company’s bank. At December 31, 2013, the Company had no cash equivalents as the full balance of cash and cash equivalents was held as cash. At December 31, 2012, the Company had $6,667 of overnight repurchase agreements in cash equivalents, which represent less than 3% and 4% of the Company’s total assets and equity, respectively.

Accounts Receivable Allowances—The Company maintains allowances for doubtful accounts based on the Company’s review and assessment of payment history and its estimate of the ability of each customer to make payments on amounts invoiced. If the financial condition of any of its customers were to deteriorate, additional allowances might be required. From time to time the Company must adjust its estimates. Changes in estimates of the collection risk related to accounts receivable can result in decreases and increases to current period net income.

Inventories—Inventories are stated at the lower of cost or market, with cost determined using the first-in, first-out method. Inventory writedowns for unprocessed donor tissue are recorded based on the estimated amount of inventory that will not pass the quality control process based on historical data, and the amount of inventory that is not readily distributable or is unusable. In addition, provisions for inventory writedowns are estimated for tissue in process inventory that is not readily distributable or is unusable. Any implantable donor tissue deemed to be obsolete is included in the writedown at the time the determination is made. Non-tissue inventory is evaluated for obsolescence and excess quantities by analyzing inventory levels, historical loss trends, expected product lives, product at risk of expiration, sales levels by product and projections of future sales demand.

Recalls—The Company accrues the estimated cost of recalls at the date the recall is initiated. The cost of recalls is primarily comprised of implant replacement costs. The Company had four recalls in the year ended December 31, 2013, and two recalls in each of the years ended December 31, 2012 and 2011. The Company incurred immaterial costs related to all of the recalls for the years ended December 31, 2013, 2012 and 2011.

Surgical Instruments—Surgical instruments which are included in property, plant and equipment are handheld devices used by surgeons during implant procedures. The Company retains title to the surgical instruments. Depreciation for surgical instruments is included in selling and marketing expenses in the accompanying consolidated statements of comprehensive (loss) income.

Property, Plant and Equipment—Property, plant and equipment are stated at cost less accumulated depreciation. The cost of equipment under capital leases and leasehold improvements is amortized on the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Depreciation is computed on the straight-line method over the following estimated useful lives of the assets:

Buildings

25 to 40 years

Building improvements and leasehold improvements

8 to 40 years

Processing equipment

7 to 10 years

Office equipment, furniture and fixtures

5 to 7 years

Computer hardware and software

3 years

Surgical instruments

3 years

Software Costs—Included in property, plant and equipment are costs related to purchased software that are capitalized.

Debt Issuance Costs—Debt issuance costs include costs incurred to obtain financing and are amortized using the straight-line method, which approximates the effective interest method, over the life of the related debt. Debt issuance costs are included in other assets—net in the accompanying consolidated balance sheets.

Long-Lived Assets—The Company periodically evaluates the period of depreciation or amortization for long-lived assets to determine whether current circumstances warrant revised estimates of useful lives. The Company reviews its property, plant and equipment for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to the net undiscounted cash flows expected to be generated by the asset. An impairment loss would be recorded for the excess of net carrying value over the fair value of the asset impaired. The fair value is estimated based on expected discounted future cash flows. The results of impairment tests are subject to management’s estimates and assumptions of projected cash flows and operating results. Changes in assumptions or market conditions could result in a change in estimated future cash flows and the likelihood of materially different reported results.

Goodwill—FASB Accounting Standards Codification (“ASC”) 350, Goodwill and Other Intangible Assets (“FASB ASC 350”), requires companies to test goodwill for impairment on an annual basis at the reporting unit level (or an interim basis if an event occurs that might reduce the fair value of a reporting unit below its carrying value). The Company has one reporting unit and the annual impairment test is performed at each year-end unless indicators of impairment are present and require more frequent testing. The Company did not have any identifiable intangible assets with indefinite useful lives as of December 31, 2013 or 2012.

Goodwill is tested for impairment annually by comparing the fair value of the reporting unit to its carrying amount, including goodwill. The Company adopted ASU No. 2011-08, Intangibles – Goodwill and Other: Testing Goodwill for Impairment, which permits the consideration of qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. If the Company determines the fair value is more-likely- than-not greater than its carrying amount, no additional testing s considered necessary. However, if the Company determines the fair value is more-likely-than-not below the carrying value of the reporting until, the Company performs the two step goodwill impairment test. If the two step goodwill impairment test is required, an income approach and a market approach are utilized. The conclusion from these two approaches are generally weighted equally and then adjusted to incorporate a control premium or acquisition premium that reflects the additional amount a buyer is willing to pay for elements of control and for a premium that reflects the buyer’s perception of its ability to add value through synergies.

In general, the income approach employs a discounted cash flow model that considers 1) assumptions that marketplace participants would use in their estimates of fair value, including the cash flow period, terminal values based on a terminal growth rate and the discount rate, 2) current period actual results, and 3) projected results for future periods that have been prepared and approved by senior management of the Company. The forecasted cash flows do not include synergies that a marketplace participant would be expecting to achieve.

The market approach employs market multiples from guideline public companies operating in our industry. Estimates of fair value are derived by applying multiples based on revenue and earnings before interest, taxes, depreciation and amortization (“EBITDA”) adjusted for size and performance metrics relative to peer companies. A control premium was included in determining the fair value under this approach.

If the carrying amount of the reporting unit exceeds its calculated fair value, the second step of the goodwill impairment test is performed in accordance with FASB ASC 350 to measure the amount of the impairment loss, if any.

Both approaches used in the analysis have a degree of uncertainty. Potential events or changes in circumstances which could impact the key assumptions used in our goodwill impairment evaluation are as follows:

•

Change in peer group or performance of peer group companies

•

Change in the Company’s markets and estimates of future operating performance

•

Change in the Company’s estimated market cost of capital

•

Change in implied control premiums related to acquisitions in the medical device industry.

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include securing synergies that are specific to our business and not available to other market participants and are expected to increase revenues and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio.

Intangible Assets—Intangible assets generally consist of patents, acquired exclusivity rights, licensing rights, trademarks, customer lists, non-compete agreements, distribution agreements, and procurement contracts. Patents and trademarks are amortized on the straight-line method over the shorter of the remaining protection period or estimated useful lives of between 8 and 16 years. The acquired exclusivity rights are being amortized over eight years, the remaining term of the amended distribution agreement. Licensing rights, customer lists, non-compete agreements, distribution agreements, and procurement contracts are amortized over estimated useful lives of between 5 to 25 years.

Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset or asset group may not be recoverable. The Company had one asset group for the year ended December 31, 2013. The recoverability test is described in the Company’s accounting policy for long-lived assets set forth above.

Research and Development Costs—Research and development costs, including the cost of research and development conducted for others and the cost of contracted research and development, are expensed as incurred.

Revenue Recognition—Revenue is recognized upon shipping, or receipt by the Company’s customers of the implant, depending on the Company’s distribution agreements with the Company’s customers or distributors. Other revenues are recognized when all significant contractual obligations have been satisfied.

The Company permits returns of implants in accordance with the terms of contractual agreements with customers if the implant is returned in a timely manner, in unopened packaging, and from the normal channels of distribution. Allowances for returns are provided based upon analysis of the Company’s historical patterns of returns matched against the revenues from which they originated.

The Company records estimated implant returns, discounts, rebates and other distribution incentives as a reduction of revenue in the same period revenue is recognized. Estimates of implant returns are recorded for anticipated implant returns based on historical distributions and returns information. Estimates of discounts, rebates and other distribution incentives are recorded based on contractual terms, historical experience and trend analysis.

Other Revenues—Other revenues consists of tissue recovery fees, biomedical laboratory fees, recognition of previously deferred revenues, shipping fees, distribution of reproductions of our allografts to distributors for demonstration purposes and restocking fees.

Stock-Based Compensation Plans—The Company accounts for its stock-based compensation plans in accordance with FASB ASC 718, Accounting for Stock Compensation. FASB ASC 718 requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors, including employee stock options and restricted stock. Under the provisions of FASB ASC 718, and U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 107, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight-line basis over the requisite service period of the entire award (generally the vesting period of the award).

Income Taxes—The Company uses the asset and liability method of accounting for income taxes. Deferred income taxes are recorded to reflect the tax consequences on future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to amounts which are more likely than not to be realized.

Earnings Per Share—Basic earnings per share (“EPS”) is computed by dividing earnings attributable to common stockholders by the weighted-average number of common shares outstanding for the periods. Diluted EPS reflects the potential dilution of securities that could share in the earnings. A reconciliation of the number of common shares used in the calculation of basic and diluted EPS is presented below:

Year Ended December 31,

2013

2012

2011

Basic shares

56,258,624

55,861,957

55,150,886

Effect of dilutive securities:

Stock options

—

206,838

203,789

Diluted shares

56,258,624

56,068,795

55,354,675

Options to purchase 5,518,604 shares of common stock at prices ranging from $2.54 to $13.52 per share which were outstanding as of December 31, 2013 were not included in the computation of diluted EPS because dilutive shares are not factored into the calculation of EPS when a loss from continuing operations is reported as they would be anti-dilutive.

Options to purchase 5,083,834 shares of common stock at prices ranging from $2.54 to $14.95 per share which were outstanding as of December 31, 2012 were included in the computation of diluted EPS because dilutive shares are factored into the calculation of EPS when a profit from continuing operations is reported.

Options to purchase 5,636,892 shares of common stock at prices ranging from $1.76 to $14.95 per share which were outstanding as of December 31, 2011 were included in the computation of diluted EPS because dilutive shares are factored into the calculation of EPS when a profit from continuing operations is reported.

For the year ended December 31, 2013, 50,000 shares of convertible preferred stock were anti-dilutive on an as if-converted basis and were not included in the computation of diluted net loss per common share.

Merger_with_Pioneer_Surgical_T

Merger with Pioneer Surgical Technology, Inc.	12 Months Ended
Merger with Pioneer Surgical Technology, Inc.	Dec. 31, 2013
Business Combinations [Abstract]	'
Merger with Pioneer Surgical Technology, Inc.	'
	3. Merger with Pioneer Surgical Technology, Inc.
	On July 16, 2013, the Company completed its acquisition of Pioneer. Under the terms of the merger agreement dated June 12, 2013, the Company acquired Pioneer for $126,307 in cash. The transaction was funded through a combination of cash on hand, a new credit facility and a concurrent private placement of convertible preferred equity. The Company obtained from Toronto-Dominion Bank, N.A., TD Securities “USA” LLC (“TD Bank”) and Regions Bank, a 5 year, $80,000 senior secured facility, which includes a $60,000 term loan and a $20,000 revolving credit facility, that matures on July 16, 2018 with a variable interest rate between 100 and 300 basis points in excess of the one month LIBOR rate. The $20,000 revolving credit facility replaced the Company’s previous $15,000 U.S. credit facility.
	Additionally, the Company received $50,000 in gross proceeds from a private placement of convertible preferred equity to WSHP Biologics Holdings, LLC, (“WSHP”), a leading healthcare-focused private equity firm. The convertible preferred stock is convertible into shares of the Company’s common stock. The convertible preferred stock will also accrue dividends at a rate of 6% per year. In 2013, the Company capitalized $1,989 in financing costs associated with the preferred stock issuance and the debt issuance and expensed $6,004 of acquisition costs. The acquisition costs are reflected separately in the accompanying Consolidated Statements of Comprehensive (Loss) Income.
	The Company has accounted for the acquisition of Pioneer under ASC 805, Business Combinations. Pioneer’s results of operations are included in the consolidated financial statements for periods ending after July 16, 2013, the acquisition date.
	The purchase price was financed as follows:


			(In thousands)
	Cash proceeds from term loan		$	60,000
	Net cash proceeds from preferred share issuance			48,710
	Cash from RTI Surgical			17,597

	Total purchase price		$	126,307

	The table below represents an allocation of the total consideration to Pioneer’s tangible and intangible assets and liabilities based on management’s preliminary estimate of their respective fair values as of July 16, 2013.


	Inventories		$	35,972
	Accounts receivable			10,567
	Other current assets			6,059
	Property, plant and equipment			15,258
	Other assets			13,260
	Current liabilities			(10,893	)
	Other long-term liabilities			(19,841	)

	Net tangible assets acquired			50,382
	Other intangible assets			23,100
	Goodwill			52,825

	Total net assets acquired		$	126,307

	Total net assets acquired as of July 16, 2013 are all part of the Company’s only operating segment. Fair values are based on management’s preliminary estimates and assumptions including variations of the income approach, the cost approach and the market approach.
	The Company believes that the acquisition of Pioneer offers the potential for substantial strategic and financial benefits. The transaction will enhance the Company’s existing core competency in biologics processing with the addition of Pioneer’s core competency in metals and synthetics. The Company believes the acquisition will enhance stockholder value through, among other things, enabling the Company to capitalize on the following strategic advantages and opportunities:

		•		Diversification of our implant portfolio.

		•		Expansion of our direct distribution and marketing organizations.

		•		Enhancement of our current international business.

		•		Improvement of our margin profile and revenue growth opportunities.
	These potential benefits resulted in the Company paying a premium for Pioneer resulting in the recognition of goodwill. The $52,825 of goodwill was assigned to the Company’s only operating segment.
	The fair value of receivables acquired is $10,567, with the gross contractual amount being $11,712, of which $1,145 was not expected to be collected.
	The amount of Pioneer’s revenues and net income since the July 16, 2013 acquisition date, included in the Company’s Consolidated Statement of Comprehensive (Loss) Income for the year ended December 31, 2013 are $35,994 and $894, respectively.
	The following unaudited pro forma information shows the results of the Company’s operations as though the acquisition had occurred as of the beginning of that period (in thousands, except per share data):


			December 31,
			2013			2012
	Revenues		$	243,001		$	266,293
	Net (loss) income applicable to common shares			(5,597	)		4,636
	Basic net (loss) income per share			(0.10	)		0.08
	Diluted net (loss) income per share			(0.10	)		0.08
	The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the merger taken place as of the beginning of the periods presented, or the results that may occur in the future.
	These amounts have been calculated to reflect the additional depreciation, amortization, and interest expense that would have been incurred assuming the fair value of adjustments and borrowings occurred on January 1, 2012 and January 1, 2013, together with the consequential tax effects. In addition, these amounts exclude costs incurred which are directly attributable to the acquisition, and which do not have a continuing impact on the combined companies’ operating results.
	The Company expects to complete its analysis of the purchase price allocation by the third quarter of 2014.

Acquisition_of_Recovery_Group

Acquisition of Recovery Group	12 Months Ended
Acquisition of Recovery Group	Dec. 31, 2013
Text Block [Abstract]	'
Acquisition of Recovery Group	'
	4. Acquisition of Recovery Group
	On December 28, 2012, RTIDS acquired certain assets related to the tissue procurement operations of a third party donor recovery agency. Under the terms of the asset transfer agreement, the maximum purchase price is $3,900 in cash, of which $3,000 was paid at closing. In addition to the $3,000 closing payment, RTIDS agreed to pay the third party donor recovery agency up to an additional $900 in connection with the assignment to RTIDS of contracts with designated hospitals and medical examiners, of which RTIDS paid $861 in 2013. The remaining balance of the contingent payment is recorded in accrued expenses and within thirty days following the end of each calendar quarter during 2014, RTIDS shall pay the third party donor recovery agency the additional closing costs for the designated hospital contracts assigned or relationships transferred during the quarter for which the applicable payment is due.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	5. Stock-Based Compensation
	The Company has five stock-based compensation plans under which employees, consultants and outside directors have received stock options and restricted stock awards. The Company’s policy is to grant stock options at an exercise price equal to 100% of the market value of a share of common stock at closing on the date of the grant. Stock options generally have ten-year contractual terms and vest over a one to five year period from the date of grant. The Company’s policy is to grant restricted stock awards at a fair value equal to 100% of the market value of a share of common stock at closing on the date of the grant. Restricted stock awards generally vest over one to three year periods.
	1998 Stock Option Plan, 2004 Equity Incentive Plan and 2010 Equity Incentive Plan—The Company adopted equity incentive plans in 1998 (the “1998 Plan”), 2004 (the “2004 Plan”) and 2010 (the “2010 Plan”), which provide for the grant of incentive and nonqualified stock options and restricted stock to key employees, including officers and directors of the Company and consultants and advisors. The 1998 Plan, 2004 Plan and 2010 Plan allow for up to 4,406,400, 2,000,000 and 5,000,000 shares, respectively, of common stock to be issued with respect to awards granted. New stock options may no longer be awarded under the 1998 Plan.

	TMI 1996 Stock Option Plan and TMI 2006 Incentive and Non-Statutory Stock Option Plan—In connection with the merger with TMI, the Company assumed the TMI 1996 Stock Option Plan and the TMI 2006 Incentive and Non-Statutory Stock Option Plan (“TMI Plans”). The TMI Plans allow for 4,880,000 and 1,830,000 shares of common stock, respectively, which may be issued with respect to stock options granted to former TMI employees or employees of the Company hired subsequent to the TMI acquisition. New stock options may no longer be awarded under the TMI 1996 Stock Option Plan.
	The Company uses the Black-Scholes model to value its stock option grants under FASB ASC 718 and expenses the related compensation cost using the straight-line method over the vesting period. The fair value of stock options is determined on the grant date using assumptions for the expected term, expected volatility, dividend yield, and the risk free interest rate. The term assumption is primarily based on the contractual vesting term of the option and historic data related to exercise and post-vesting cancellation history experienced by the Company. The Company uses the simplified method for estimating the expected term used to determine the fair value of options under FASB ASC 718. The expected term is determined separately for options issued to the Company’s directors and to employees. The Company’s anticipated volatility level is primarily based on the historic volatility of the Company’s common stock. The Company’s model includes a zero dividend yield assumption, as the Company has not historically paid nor does it anticipate paying dividends on its common stock. The risk free interest rate approximates recent U.S. Treasury note auction results with a similar life to that of the option. The Company’s model does not include a discount for post-vesting restrictions, as the Company has not issued awards with such restrictions. The period expense is then determined based on the valuation of the options, and at that time an estimated forfeiture rate is used to reduce the expense recorded. The Company’s estimate of pre-vesting forfeitures is primarily based on the recent historical experience of the Company, and is adjusted to reflect actual forfeitures as the options vest.
	The following weighted-average assumptions were used to determine the fair value of options under FASB ASC 718:


		Year Ended December 31,
		2013			2012			2011
	Expected term (years)		6.5			6.5			6.5
	Risk free interest rate		1.3	%		1.38	%		2.72	%
	Volatility factor		47.5	%		64.83	%		66.27	%
	Dividend yield		—			—			—
	Stock Options
	Outstanding options under all option plans vest over a one to five year period. Options expire ten years from the date of grant.
	As of December 31, 2013, there was $3,260 of total unrecognized stock-based compensation related to nonvested stock options. That expense is expected to be recognized over a weighted-average period of 3.13 years.

	Stock options outstanding, exercisable and available for grant at December 31, 2013 are summarized as follows:


		Number of			Weighted			Weighted			Aggregate
		Shares			Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price			Contractual
								Life (Years)
	Outstanding at January 1, 2013		5,083,834		$	5.03
	Granted		1,066,500			3.48
	Exercised		(110,590	)		3
	Forfeited or expired		(521,140	)		6.56

	Outstanding at December 31, 2013		5,518,604		$	4.63			5.76		$	1,026

	Vested or expected to vest at December 31, 2013		5,357,211		$	4.66			5.67		$	1,000

	Exercisable at December 31, 2013		3,188,204		$	5.42			4.11		$	542

	Available for grant at December 31, 2013		2,752,053

	The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value of outstanding stock options for which the fair market value of the underlying common stock exceeds the respective stock option exercise price.
	For the years ended December 31, 2013, 2012 and 2011, the Company recognized stock-based compensation as follows:


		Year Ended December 31,
		2013			2012			2011
	Stock-based compensation:
	Costs of processing and distribution	$	132		$	163		$	207
	Marketing, general and administrative		2,028			1,785			1,705
	Research and development		60			130			61

	Total	$	2,220		$	2,078		$	1,973

	For the years ended December 31, 2013, 2012, and 2011, the Company recognized total income tax benefits from stock-based compensation of $883, $801, and $660, respectively.
	Other information concerning stock options are as follows:


		Year Ended December 31,
		2013			2012			2011
	Weighted average fair value of stock options granted	$	1.66		$	2.43		$	1.71
	Aggregate intrinsic value of stock options exercised		117			172			926
	The aggregate intrinsic value of stock options exercised in a period represents the pre-tax cumulative difference between the fair market value of the underlying common stock and the stock option exercise prices, of the stock options exercised during the period.
	Restricted Stock Awards
During 2013, the Company granted 290,579 shares of restricted stock with a weighted-average grant date fair value of $3.71 per share which vest over one and three year periods. As of December 31, 2013, there was $765 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 1.13 years.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	6. Inventories
	Inventories by stage of completion are as follows:


		December 31,
		2013		2012
	Unprocessed tissue and raw materials	$	31,468	$	25,962
	Tissue and work in process		39,417		28,379
	Implantable tissue and finished goods		33,102		20,071
	Supplies		2,139		2,097

		$	106,126	$	76,509

	For the years ended December 31, 2013, 2012, and 2011, the Company had inventory write-downs of $1,785, $3,114 and $4,840, respectively, relating primarily to inventory obsolescence. Inventory at December 31, 2013 includes $5,708 of purchase price adjustments applied to the acquired Pioneer inventory, which is expected to be expensed in the first quarter of 2014.

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	7. Property, Plant and Equipment
	Property, plant and equipment are as follows:


		December 31,
		2013			2012
	Land	$	2,618		$	2,169
	Buildings and improvements		50,106			45,220
	Processing equipment		43,309			31,681
	Surgical instruments		5,012			—
	Office equipment, furniture and fixtures		3,994			2,831
	Computer equipment and software		6,152			5,029
	Construction in process		16,156			7,329
	Equipment under capital leases:
	Processing equipment		396			396
	Computer equipment		744			744
	Office equipment		152			—

			128,639			95,399
	Less accumulated depreciation		(53,901	)		(45,755	)

		$	74,738		$	49,644

	Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $8,267, $5,970, and $6,039, respectively.

Goodwill

Goodwill	12 Months Ended
Goodwill	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	8. Goodwill
	The changes in the carrying amount of goodwill for the years ended December 31, 2013 and 2012, respectively, are as follows:


		Year Ended December 31,
		2013		2012
	Balance at January 1	$	2,062	$	—
	Goodwill acquired during the period		52,825		2,062

		$	54,887	$	2,062


	On July 16, 2013, the Company completed its acquisition of Pioneer paying a premium, which resulted in the recognition of goodwill. Goodwill of $52,825 was assigned to the Company’s one operating segment. Goodwill at December 31, 2013 includes the excess of the purchase price of the certain assets related to the acquisitions of Pioneer in 2013 and procurement operations of the third party donor recovery agency in 2012 over the sum of the amounts assigned to assets acquired. The Company performed its annual goodwill impairment test as of December 31, 2013 and concluded that there was no impairment of goodwill.

Other_Intangible_Assets

Other Intangible Assets	12 Months Ended
Other Intangible Assets	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Other Intangible Assets	'
	9. Other Intangible Assets
	Other intangible assets are as follows:


		December 31, 2013				December 31, 2012
		Gross		Accumulated		Gross		Accumulated
		Carrying		Amortization		Carrying		Amortization
		Amount				Amount
	Patents	$	10,637	$	1,935	$	4,616	$	1,443
	Acquired exclusivity rights		2,941		2,787		2,941		2,415
	Acquired licensing rights		10,850		5,326		10,850		4,115
	Marketing and procurement intangible assets		22,098		2,692		4,223		891

	Total	$	46,526	$	12,740	$	22,630	$	8,864

	As a result of the acquisition of Pioneer on July 16, 2013, the Company acquired certain identifiable intangible assets in the amount of $23,100 consisting primarily of patents and distribution agreements which will be amortized over their estimated useful lives of between 5 to 12 years. The weighted average term of the patents and distribution agreements acquired as part of the Pioneer acquisition was 10.5 and 9.2 years, respectively.
	On December 28, 2012, RTIDS acquired certain assets related to the tissue procurement operations of a third party donor recovery agency. The transaction was accounted for using the purchase method of accounting in accordance with ASC 805. The identifiable intangible assets acquired in the amount of $1,838 consist primarily of tissue procurement contracts and a non-compete agreement which will be amortized over their estimated useful lives of between 5 to 20 years.
	On September 10, 2010, the Company entered into an Exclusive License Agreement with Athersys, Inc. (“Athersys”), pursuant to which Athersys will provide the Company access to its Multipotent Adult Progenitor Cell (“MAPC”) technologies to develop and commercialize MAPC technology-based biologic implants for certain orthopedic applications. In consideration for the Exclusive License, the Company agreed to pay Athersys the following: 1) a non-refundable $3,000 license fee, payable in three time-based $1,000 installments, the last of which was paid in the first quarter of 2011, 2) payment of $2,000 contingent upon successful achievement of certain development milestones which the Company paid in 2012, and 3) up to $32,500 contingent upon achievement of certain cumulative revenue milestones in future years. In addition, the Company pays Athersys royalties from the distribution of implants under a tiered royalty structure based on achievement of certain cumulative revenue milestones. The term of the Exclusive License Agreement is the longer of five years, or the remaining life of any patent or trade secret. These acquired licensing rights are being amortized to expense on a straight-line basis over the expected life of the asset.
	Amortization expense for the years ended December 31, 2013, 2012, and 2011 was $3,935, $2,023, and $1,987, respectively. At December 31, 2013, management’s estimates of future amortization expense for the next five years are as follows:


		Amortization
		Expense
	2014	$	4,400
	2015		4,000
	2016		3,400
	2017		3,300
	2018		3,300

		$	18,400

Other_Assets

Other Assets	12 Months Ended
Other Assets	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Assets	'
	10. Other Assets
	Other assets are as follows:


		December 31,
		2013		2012
	Indemnification asset	$	13,000	$	—
	Other		1,332		713

		$	14,332	$	713

	Other assets include $13,000 of indemnification assets recognized on the date of the acquisition of Pioneer. Under the acquisition agreement, Pioneer deposited $13,000 in an escrow account and indemnified the Company for up to $13,000 for various outstanding legal and contractual issues as of December 31, 2013. In conjunction with recording the indemnification asset, the Company also recorded a corresponding $13,000 indemnification liability.
	The Company recognized interest expense associated with the amortization of its debt issuance costs which is included in Other in the table above, for the years ended December 31, 2013, 2012 and 2011 of $57, $23 and $22, respectively.

Accrued_Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
Accrued Expenses	'
	11. Accrued Expenses
	Accrued expenses are as follows:


		December 31,
		2013		2012
	Accrued compensation	$	3,817	$	6,279
	Accrued donor recovery fees		5,771		3,845
	Accrued restructuring charges		2,609		—
	Accrued distributor commissions		2,059		462
	Accrued taxes		200		3,950
	Contingent consideration		39		900
	Other		7,983		5,158

		$	22,478	$	20,594

	The Company accrues for the estimated donor recovery fees due to third party recovery agencies as tissue is received.

Short_and_LongTerm_Obligations

Short and Long-Term Obligations	12 Months Ended
Short and Long-Term Obligations	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Short and Long-Term Obligations	'
	12. Short and Long-Term Obligations
	Short and long-term obligations are as follows:


		December 31,
		2013			2012
	Term loan	$	60,000		$	—
	Credit facilities		8,911			—
	Capital leases		139			120

	Total		69,050			120
	Less current portion		(1,344	)		(116	)

	Long-term portion	$	67,706		$	4

	On July 16, 2013, the Company obtained from TD Bank and Regions Bank, a 5 year, $80,000 senior secured facility, which includes a $60,000 term loan and a $20,000 revolving credit facility, that matures on July 16, 2018 with a variable interest rate between 100 and 300 basis points in excess of the one month LIBOR rate. At December 31, 2013, the interest rate for the term loan and revolving credit facility is 2.42%. The facility is secured by substantially all the assets of the Company and its subsidiaries and guaranteed by the Company’s domestic subsidiaries, other than RTIDS. The $20,000 revolving credit facility replaced the Company’s previous $15,000 U.S. credit facility. The term loan facility includes an interest only period of September 30, 2013 through December 31, 2014 with a final balloon principal payment at the end of the loan agreement. The new credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, payments of dividends, require a minimum cash balance on hand of $10,000, and require certain financial covenant ratios.

	In addition to the credit facility with TD Bank and Regions Bank, the Company has three credit facilities with German banks as of December 31, 2013. The total available credit on the Company’s four revolving credit facilities at December 31, 2013 was $13,436. As of December 31, 2013, there was $8,250 outstanding on the revolving credit facility with TD Bank and Regions Bank.
	Under the terms of the revolving credit facilities with three German banks, the Company may borrow up to 1,700 Euro, or approximately $2,340, for working capital needs. The 1,000 Euro revolving credit facility is secured by a mortgage on the Company’s German facility. The 500 Euro revolving credit facility is secured by accounts receivable of the Company’s German subsidiary. The 200 Euro revolving credit facility is unsecured. The current interest rates for these lines of credit vary from 3.30% to 6.00%. As of December 31, 2013, there was $661 outstanding on the 1,000 Euro revolving credit facility with a German bank.
	The Company was in compliance with the financial covenants related to its term loans and credit facilities as of December 31, 2013.
	The Company has capital leases with interest rates ranging from 1.49% to 8.46% and maturity dates through 2017. The $139 representing future maturities of capital leases includes interest in the amount of $3. The present value of minimum lease payments as of December 31, 2013 was $136.
	As of December 31, 2013, contractual maturities of short and long-term obligations are as follows:


		Term			Credit			Capital		Total
		Loan			Facilities			Leases		Total
	2014	$	625		$	661		$	58	$	1,344
	2015		5,250			—			44		5,294
	2016		4,500			—			32		4,532
	2017		5,250			—			5		5,255
	2018		44,375			8,250			—		52,625

		$	60,000		$	8,911		$	139	$	69,050

Other_LongTerm_Liabilities

Other Long-Term Liabilities	12 Months Ended
Other Long-Term Liabilities	Dec. 31, 2013
Text Block [Abstract]	'
Other Long-Term Liabilities	'
	13. Other Long-Term Liabilities
	Other long-term liabilities are as follows:


		December 31,
		2013		2012
	Indemnification liability	$	13,000	$	—
	Other		446		698

		$	13,446	$	698

	As described in Note 10, the Company recorded a $13,000 indemnification liability on the date of the acquisition of Pioneer.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	14. Income Taxes
	The Company’s income tax benefit (provision) consists of the following components:


			Year Ended December 31,
			2013				2012				2011
	Current:
	Federal		$	127			$	(1,189	)		$	(842	)
	State			167				(806	)			(925	)
	International			219				(407	)			(2,965	)

	Total current			513				(2,402	)			(4,732	)

	Deferred:
	Federal			8,017				(1,299	)			(20	)
	State			1,675				(181	)			630
	International			905				(160	)			896

	Total deferred			10,597				(1,640	)			1,506

	Total income tax benefit (provision)		$	11,110			$	(4,042	)		$	(3,226	)

	The components of the deferred tax assets and liabilities consisted of the following at:


			December 31, 2013								December 31, 2012
			Deferred Income Tax								Deferred Income Tax
			Asset				Liability				Asset			Liability
	Current:
	International		$	—			$	(195	)		$	26		$	—
	Allowance for bad debts			400				—				121			—
	Inventory			10,340				—				4,766			—
	Net operating losses			4,040				—				—			—
	Tax credits			1,630				—				1,234			—
	Deferred compensation			3,620				—				3,172			—
	Deferred revenue			2,027				—				1,886			—
	Accrued liabilities			2,643								1,348			—
	Other			—				(123	)			45			—

	Total current			24,700				(318	)			12,598			—

	Noncurrent:
	International			818				—				—			(473	)
	Fixed assets and intangibles			—				(7,615	)			—			(1,565	)
	Investments			2,085				—				2,061			—
	Net operating losses			1,775				—				469			—
	Tax credits			3,768				—				1,961			—
	Deferred revenue			5,066				—				6,195			—
	Accrued liabilities			24				—				—			—
	Valuation allowance			(469	)			—				(469	)		—

	Total noncurrent			13,067				(7,615	)			10,217			(2,038	)

	Total		$	37,767			$	(7,933	)		$	22,815		$	(2,038	)

	The Company expects its deferred tax assets of $29,834, net of the valuation allowance at December 31, 2013 of $469, to be realized through the generation of future taxable income and the reversal of existing taxable temporary differences.
	Valuation allowances are established when necessary to reduce deferred tax assets to amounts which are more likely than not to be realized. As such, valuation allowances of $469 have been established at both December 31, 2013 and 2012, against a portion of the deferred tax assets relating to certain state net operating loss carryforwards.

	The Company recorded a tax benefit from the exercise of stock options in the amount of $315, $1,107, and $313 for the years ended December 31, 2013, 2012 and 2011, respectively.
	As of December 31, 2013, the Company has state net operating loss carryforwards of $20,169 that will expire in the years 2017 through 2033.
	As of December 31, 2013, the Company has research tax credit carryforwards of $6,677 that will expire in years 2025 through 2033. As of December 31, 2013, the Company has alternative minimum tax credit carryforwards of $827.
	On January 2, 2013, the American Taxpayer Relief Act of 2012 (“ATRA”) was signed into law. The ATRA retroactively extended the research tax credit to the beginning of 2012 through 2013. Under ASC 740, Accounting for Income Taxes, the effects of the tax legislation are recognized upon enactment. Therefore, the Company recognized the tax benefit associated with the 2012 and 2013 research tax credits in 2013.
	U.S. income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries. It is not practicable to estimate the amount of tax that might be payable. The Company’s intention is to permanently reinvest earnings in its foreign subsidiaries. As of December 31, 2013 and 2012, the amount of undistributed earnings related to our foreign subsidiaries considered to be indefinitely reinvested was $7,365 and $10,364, respectively.
As of December 31, 2013, the Company’s deferred tax assets were primarily attributable to U.S. federal net operating loss and credit carryforwards. The Company evaluates the need for deferred tax asset valuation allowances based on a more likely than not standard. The ability to realize deferred tax assets depends on the ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction.
The assessment regarding whether a valuation allowance is required or should be adjusted also considers all available positive and negative evidence factors. It is difficult to conclude a valuation allowance is not required when there is significant objective and verifiable negative evidence, such as cumulative losses in recent years. The Company utilizes a rolling three years of actual results as the primary measure of cumulative losses in recent years.
When evaluating whether the Company has overcome the significant negative evidence that resulted from cumulative losses in recent years, the Company adjusted its historical loss for items that the Company determined were not indicative of its ability to generate taxable income in future years. The Company is in a cumulative income position after adjusting for the items that were not indicative of its ability to generate taxable income in future years. The Company considers this objectively verifiable evidence that its current operations existing on December 31, 2013 have consistently demonstrated the ability to operate at a profit. The Company believes that this evidence is sufficient to overcome the unadjusted cumulative losses in recent years.
The Company has a history of utilizing 100 percent of its deferred taxes assets before they expire and the forecasts of taxable earnings project a complete realization of all federal deferred tax assets before they expire, including under stressed scenarios.
Upon considering all of the available positive and negative evidence, and the extent to which that evidence was objectively verifiable, the Company determined that the positive evidence outweighed the negative evidence and the deferred tax assets are more-likely-than-not realizable, as of and for the year ended December 31, 2013.
The Company will continue to regularly assess the realizability of our deferred tax assets. Changes in historical earnings performance and future earnings projections, among other factors, may cause the Company to adjust its valuation allowance, which would impact the Company’s income tax expense in the period the Company determines that these factors have changed.
As of December 31, 2013, the Company has $2,825 of unrecognized tax benefits, of which $720 were recorded in other liabilities and $2,105 of unrecognized tax benefits were recorded net against deferred tax assets in the accompanying consolidated balance sheet.
The Company’s unrecognized tax benefits are summarized as follows:


		Year Ended December 31,
		2013				2012				2011
Opening balance		$	1,797			$	1,674			$	2,341
(Reductions) additions based on tax positions related to the current year			(174	)			274				154
Additions for tax positions of prior years			1,337				336				—
Reductions for tax positions of prior years			(135	)			(487	)			(821	)

		$	2,825			$	1,797			$	1,674

The unrecognized tax benefits if recognized, would favorably impact the Company’s effective tax rate. The Company believes it is reasonably possible that its unrecognized tax benefits will decrease and be recognized in the next twelve months by up to $895 due to completing a tax examination with the U.S. and German taxing authorities and confirmation from the Florida Department of Revenue concerning which sourcing method the Company should use to file its Florida income tax returns.
The Company’s policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in the provision for income taxes. There were no interest and penalties recorded in 2013, 2012 and 2011 and no interest and penalties accrued at December 31, 2013 and 2012.
The Company is undergoing an examination by the Internal Revenue Service (“IRS”). The IRS examination covers the 2010 tax year. In addition, one of the Company’s foreign subsidiaries is undergoing an examination by the German tax authorities. The foreign examination covers the foreign subsidiary’s 2006 through 2009 tax years.

The effective tax rate differs from the statutory federal income tax rate for the following reasons:


		Year Ended December 31,
		2013				2012				2011
Statutory federal rate			35	%			35	%			35	%
State income taxes—net of federal tax benefit			4.14	%			5.16	%			1.95	%
International operations			(0.46	%)			(2.23	%)			—
Non-deductible expenses			(4.27	%)			—				—
Research tax credits			3.56	%			(2.06	%)			(3.30	%)
Domestic production activities deduction			—				(2.29	%)			—
Unrecognized tax benefits			0.86	%			—				(6.90	%)
Other reconciling items, net			(0.42	%)			(1.10	%)			1.05	%

Effective tax rate			38.41	%			32.48	%			27.8	%

For the years ended December 31, 2013, 2012 and 2011, the Company had no individually significant other reconciling items.

Preferred_Stock

Preferred Stock	12 Months Ended
Preferred Stock	Dec. 31, 2013
Equity [Abstract]	'
Preferred Stock	'
	15. Preferred Stock
	Preferred stock is as follows:


		December 31,
		2013			2012
	Preferred shares issuance	$	50,000		$	—
	Preferred shares issuance costs		(1,290	)		—

	Net proceeds		48,710			—
	Amortization of preferred shares issuance costs		77			—
	Accrued dividend payable		750			—

		$	49,537		$	—

	On June 12, 2013, the Company and WSHP entered into an investment agreement. Pursuant to the terms of the investment agreement, the Company agreed to a $50,000 private placement of convertible preferred equity with WSHP. In connection with the closing of the transactions contemplated by the investment agreement, the Company and WSHP amended the investment agreement on July 15, 2013, and the Company filed a Certificate of Designation of Series A Convertible Preferred Stock creating the Series A Convertible Preferred Stock, par value $0.001 per share (the “Preferred Stock”), and establishing the designations, preferences, and other rights of the Preferred Stock. The Preferred Stock accrues dividends at a rate of 6% per annum. To the extent dividends are not paid in cash in any quarter, the dividends which have accrued on each outstanding share of Preferred Stock during such three-month period will accumulate until paid in cash. The payments of dividends may be restricted by various covenants under our new credit agreement with TD Bank and Regions Bank.
	The Preferred Stock will be convertible at the election of the holders into shares of the Company’s common stock at an initial conversion price of $4.39 per share which would result in a conversion ratio of approximately 228 shares of common stock for each share of Preferred Stock following the receipt of the stockholder approval. The Preferred Stock is convertible at the election of the Company five years after its issuance or at any time if the Company’s common stock closes at or above $7.98 per share for at least 20 consecutive trading days.
	The Company may, upon 30 days notice, redeem the Preferred Stock, in whole or in part, five years after its issuance at the initial liquidation preference of $1,000 per share of the Preferred Stock plus an amount per share equal to accrued but unpaid dividends (collectively, the “Liquidation Value”). The holders of the Preferred Stock may require the Company to redeem their Preferred Stock, in whole or in part, at the Liquidation Value seven years after its issuance or upon the occurrence of a change of control.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	16. Stockholders’ Equity
	Preferred Stock—The Company has 5,000,000 shares of preferred stock authorized under its Certificate of Incorporation of which 50,000 are currently issued and outstanding. These shares may be issued in one or more series having such terms as may be determined by the Company’s Board of Directors.

	Common Stock—The Company has 150,000,000 shares of common stock authorized. The common stock’s voting, dividend, and liquidation rights presently are not subject to or qualified by the rights of the holders of any outstanding shares of preferred stock, as the Company presently does not have any shares of preferred stock outstanding. Holders of common stock are entitled to one vote for each share held at all stockholder meetings. Shares of common stock do not have redemption rights.

Restructuring_Charges

Restructuring Charges	12 Months Ended
Restructuring Charges	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Restructuring Charges	'
	17. Restructuring Charges
	The Company instituted a restructuring plan primarily related to termination of employees and a location closure as a result of the integration activities following the acquisition of Pioneer, which resulted in $2,881 of expenses for the year ended December 31, 2013. The total estimated restructuring charges should be paid in full prior to February 28, 2015. Severance payments are made to terminated employees over periods ranging from one month to twelve months and will not have a material impact on cash flows of the Company in any quarterly period. The following table includes a rollforward of restructuring charges included in accrued expenses, see Note 11.


	Accrued restructuring charges at January 1, 2013	$	—
	Employee separation benefits accrued		2,514
	Office closure costs		367

	Subtotal restructuring charges		2,881
	Cash payments		(272	)

	Accrued restructuring charges at December 31, 2013	$	2,609

Retirement_Benefits

Retirement Benefits	12 Months Ended
Retirement Benefits	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Retirement Benefits	'
	18. Retirement Benefits
	The Company has a qualified 401(k) plan available to all U.S. employees who meet certain eligibility requirements. The 401(k) plan allows each employee to contribute up to the annual maximum allowed under the Internal Revenue Code. The Company has the discretion to make matching contributions up to 6% of the employee’s earnings. For the years ended December 31, 2013, 2012 and 2011, the amounts expensed under the plan were $1,964, $1,501 and $1,359, respectively.

Concentrations_of_Risk

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Dec. 31, 2013
Risks And Uncertainties [Abstract]	'
Concentrations of Risk	'
	19. Concentrations of Risk
	Distribution—The Company’s principal concentration of risk is related to its limited distribution channels. The Company’s revenues include the distribution efforts of fourteen independent companies with significant revenues coming from three of the distribution companies, Medtronic, Zimmer, and Davol. The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution:


		Year Ended December 31,
		2013			2012			2011
	Percent of revenues derived from:
	Distributor
	Zimmer, Inc.		17	%		14	%		12	%
	Medtronic, Inc.		16	%		18	%		19	%
	Davol, Inc.		9	%		11	%		11	%
	International		10	%		12	%		12	%
	The Company’s distribution agreements are subject to termination by either party for a variety of causes. No assurance can be given that such distribution agreements will be renewed beyond their expiration dates, continue in their current form or at similar rate structures. Any termination or interruption in the distribution of the Company’s implants through one of its major distributors could have a material adverse effect on the Company’s operations.

	Tissue Supply—The Company’s operations are dependent on the availability of tissue from human donors. For the majority of the tissue recoveries, the Company relies on the efforts of independent procurement agencies to educate the public and increase the willingness to donate bone tissue. These procurement agencies may not be able to obtain sufficient tissue to meet present or future demands. Any interruption in the supply of tissue from these procurement agencies could have a material adverse effect on the Company’s operations.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	20. Commitments and Contingencies
	Distribution Agreement with Medtronic—On October 12, 2013, the Company entered into a replacement distribution agreement with Medtronic, Inc. (“Medtronic”), pursuant to which Medtronic will distribute certain allograft implants for use in spinal, general orthopedic and trauma surgery. Under the terms of this distribution agreement, Medtronic will be a non-exclusive distributor except for certain specified implants for which Medtronic will be the exclusive distributor. Medtronic will maintain its exclusivity with respect to these specified implants unless the cumulative fees received by us from Medtronic in respect of these specified implants decline by a certain amount during any trailing 12-month period. The initial term of this distribution agreement will continue through December 31, 2017, unless earlier terminated in accordance with this distribution agreement. This initial term will automatically renew for successive five-year periods, unless either party provides written notice of its intent not to renew at least one year prior to the expiration of the initial term or the applicable renewal period. This distribution agreement superseded and replaced our prior distribution agreement with Medtronic which would have expired in accordance with its terms in June 2014.
	Exclusive License Agreement with Athersys—On September 10, 2010, the Company entered into an Exclusive License Agreement with Athersys, pursuant to which Athersys will provide the Company access to its MAPC technologies to develop and commercialize MAPC technology-based biologic implants for certain orthopedic applications. In consideration for the Exclusive License, the Company agreed to pay Athersys the following: 1) a non-refundable $3,000 license fee, payable in three time-based $1,000 installments, the last of which was paid in the first quarter of 2011, 2) payment of $2,000 contingent upon successful achievement of certain development milestones which the Company paid in 2012, and 3) up to $32,500 contingent upon achievement of certain cumulative revenue milestones in future years. In addition, the Company pays Athersys royalties from the distribution of implants under a tiered royalty structure based on achievement of certain cumulative revenue milestones. The term of this license agreement is the longer of five years, or the remaining life of any patent or trade secret. These acquired licensing rights are being amortized to expense on a straight-line basis over the expected life of the asset.
	Distribution Agreement with Zimmer Dental Inc.—On September 3, 2010, the Company and Zimmer Dental Inc. (“Zimmer Dental”), a subsidiary of Zimmer, entered into an exclusive distribution agreement, with an effective date of September 30, 2010. This distribution agreement has an initial term of ten years. Under the terms of this distribution agreement, the Company has agreed to supply sterilized allograft and xenograft implants at an agreed upon transfer price, and Zimmer Dental has agreed to be the exclusive distributor of the implants for dental and oral applications worldwide (except the Ukraine), subject to certain Company obligations under an existing distribution agreement with a third party with respect to certain implants for the dental market. In consideration for Zimmer Dental’s exclusive distribution rights, Zimmer Dental agreed to the following: 1) payment to the Company of $13,000 within ten days of the effective date (the “Upfront Payment”), 2) annual exclusivity fees (“Annual Exclusivity Fees”) paid annually for the term of the contract to be paid at the beginning of each calendar year, and, 3) escalating annual purchase minimums to maintain exclusivity. Upon occurrence of an event that materially and adversely affects Zimmer Dental’s ability to distribute the implants, Zimmer Dental may be entitled to certain refund rights with respect to the Upfront Payment and the then current Annual Exclusivity Fee, where such refund would be in an amount limited by a formula specified in this distribution agreement that is based substantially on the number of days from the occurrence of such event to the date that it is cured by the Company to the satisfaction of Zimmer Dental. The Upfront Payment, the Annual Exclusivity Fees and the fees associated with distributions of processed tissue are considered to be a single unit of accounting. Accordingly, the Upfront Payment and the Annual Exclusivity Fees are deferred as received and are being recognized as other revenues over the term of this distribution agreement based on the expected contractual escalating annual purchase minimums relative to the total contractual minimum purchase requirements in this distribution agreement. Additionally, the Company has considered the potential impact of this distribution agreement’s contractual refund provisions and does not expect these provisions to impact future expected revenue related to this distribution agreement.
	Distribution Agreement with Davol—On July 13, 2009, the Company and Davol amended their previous distribution agreement with TMI for human dermis implants. Under the amended agreement, 1) Davol paid the Company $8,000 in non-refundable fees for exclusive distribution rights for the distribution to the breast reconstruction market until July 13, 2019, 2) the exclusive worldwide distribution agreement related to the hernia market was extended to July 13, 2019, and 3) Davol agreed to pay the Company certain additional exclusive distribution rights fees contingent upon the achievement of certain revenue milestones by Davol during the duration of the contract. In the fourth quarter of 2010, Davol paid the first revenue milestone payment of $3,500. The non-refundable fees and the fees associated with distributions of processed tissue are considered to be a single unit of accounting. Accordingly, the $8,000 and $3,500 exclusivity payments have been deferred and are being recognized as other revenues on a straight-line basis over the initial term of the amended contract of ten years, and the remaining term of the amended contract, respectively. The straight-line method approximates the expected pattern of implant distribution based on this distribution agreement’s contractual annual minimum purchase requirements. Davol did not achieve certain revenue growth milestones which resulted in Davol relinquishing its exclusive distribution rights in the hernia market effective January 1, 2013. As a result, the Company recognized $1,715 of additional deferred revenue as other revenues during the first quarter of 2013 due to the acceleration of deferred revenue recognition.
	The Company’s aforementioned revenue recognition methods related to the Zimmer and Davol distribution agreements do not result in the deferral of revenue less than amounts that would be refundable in the event the agreements were to be terminated in future periods. Additionally, the Company evaluates the appropriateness of the aforementioned revenue recognition methods on an ongoing basis.
	Leases—The Company leases certain facilities, items of office equipment and vehicles under non-cancelable operating lease arrangements expiring on various dates through 2017. The facility leases generally contain renewal options and escalation clauses based upon increases in the lessors’ operating expenses and other charges. The Company anticipates that most of these leases will be renewed or replaced upon expiration. Rent expense for the years ended December 31, 2013, 2012, and 2011 was $1,529, $1,302 and $1,041, respectively, and is included as a component of marketing, general and administrative expenses.
	Future minimum lease commitments under non-cancelable operating leases as of December 31, 2013 are as follows:


		Operating
		Leases
	2014	$	1,886
	2015		1,064
	2016		353
	2017		175

		$	3,478

Legal_and_Regulatory_Actions

Legal and Regulatory Actions	12 Months Ended
Legal and Regulatory Actions	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Legal and Regulatory Actions	'
	21. Legal and Regulatory Actions
	The Company is, from time to time, involved in litigation relating to claims arising out of its operations in the ordinary course of business. The Company believes that none of these claims that were outstanding as of December 31, 2013 will have a material adverse impact on its financial position or results of operations.
	Biomedical Tissue Service, Ltd.—The Company was named as a party, along with a number of other recovery and processor defendants, in lawsuits relating to the tissue recovery practices of Biomedical Tissue Service, Ltd. (“BTS”), an unaffiliated recovery agency and BTS’s owner, the late, Michael Mastromarino, as well as several funeral homes and their owners with which BTS conducted its activities. These cases generally alleged that the Company had liability for interference with the rights of the surviving next of kin as perpetrated by BTS and the funeral homes. As a result of increased judicial clarity during the second quarter of 2012 regarding timing of litigation, and anticipated increases in legal activity and expense flowing therefrom, the Company determined that the cost of continuing an aggressive legal defense for certain of the lawsuits would be significant. Therefore, in order to mitigate the Company’s financial exposure, an agreement was reached to settle 29 of the lawsuits for which our insurer was not paying for the legal fees. Pursuant to the settlement of these lawsuits, the Company recorded a litigation settlement charge of $2,350 in the second quarter of 2012 which was paid in the third quarter of 2012.
	The Company, through its affiliation with RTIDS, currently has $2,000 in answerable indemnity insurance, with non-eroding defense limits. On July 25, 2013, the Company and attorneys for the majority of the remaining donor family cases signed an agreement to settle those cases for an upfront payment of $2,700 with a contingent interest in any recovery in the Company’s litigation with its insurer, in the amount of $300. In the event the $300 has not been recovered from the insurance company by January 15, 2015, the Company will guarantee its payment. Pursuant to the settlement of these lawsuits, the Company recorded a litigation settlement charge of $3,000 in the second quarter of 2013. The resolution of these cases related to BTS effectively brought to conclusion any reasonable probability for materially adverse impact on our business, financial conditions, or results of operations.
	Lanx, Inc. —Lanx, Inc., a subsidiary of Biomet, Inc. filed suit in the second quarter of 2013 against Pioneer in the United States District Court, District of Colorado, alleging that one of the Company’s medical devices infringes certain of Lanx’s U.S. intellectual property rights, and seeking monetary damages and threatening injunctive relief. The parties are currently in discovery and litigation is ongoing. The Company has given notice to the former Pioneer stockholders’ agent of an indemnification claim against the Pioneer escrow fund. As of January 17, 2014, the parties had reached an agreement in principle to resolve the claim with no material financial impact to the Company or its operations. Final documentation of the resolution is presently being negotiated.
	Coloplast —The Company is presently named as co-defendant along with other companies in a small number of the transvaginal surgical mesh mass tort claims being brought in various state and federal courts. The transvaginal surgical mesh litigation has as its catalyst various Public Health Notifications issued by the FDA with respect to the placement of certain transvaginal surgical mesh implants that were the subject of 510k regulatory clearance prior to their distribution. The Company does not process or otherwise manufacture for distribution in the United States any implants that were the subject of these FDA Public Health Notifications. Though the Company believes their inclusion in these cases is the result of confusion and lack of discrimination among plaintiffs’ attorneys, and that the claims presently asserted against them are product liability claims that are inapplicable to allografts, plaintiffs may attempt to amend their theory of liability and approach to the litigation, including, for example, increasing the number of cases in which the Company is named. The Company denies any allegations against itself and intends to vigorously defend itself.
	In addition to claims made directly against the Company, Coloplast, a distributor of certain allografts processed and private labeled for them under a contract with the Company, has been named as a defendant in individual transvaginal surgical mesh cases in various federal and state courts around the United States. A multidistrict litigation (“MDL”) was formed in August 2012 to consolidate federal court cases in which Coloplast is the first named defendant in the Southern District of West Virginia as part of MDL No. 2387. The cases are consolidated for purposes of pre-trial discovery and motion practice. MDLs against other major transvaginal mesh manufacturers are being heard at the same venue. Of the cases that have been filed against Coloplast, as well as claims that have not been filed but of which Coloplast is aware and has executed tolling agreements to suspend the running of statutes of limitation, Coloplast has expressed to the Company that it believes the Company is required to indemnify or defend Coloplast in those claims which allege injuries caused only by Company’s allograft implants. With respect to cases alleging the implantation of both an allograft of the Company’s and a Coloplast product, Coloplast proposes working cooperatively to defend such cases. No trial date has yet been set for any such cases, and the Company has requested additional information from Coloplast for evaluation. If, following a formal request for defense and indemnification by Coloplast in accordance with the terms and conditions of the applicable contracts, the Company either determines such indemnification and defense to be required by the Company, or if such defense and indemnification are assumed under a reservation of rights by the Company, as may be applicable, such defense and indemnification will be afforded coverage under the Company’s insurance policy subject to a reservation of rights by our insurer.
	Based on the current information available to the Company, it is not possible to evaluate and estimate with reasonable certainty the impact that current or any future transvaginal mesh litigation may have on the Company. However, based on the current information available to the Company, and to the best of our knowledge, we do not expect this to have a material impact on the financial position of the Company.
	The Company’s accounting policy is to accrue for legal costs as they are incurred.
	In October 2012, the Company received a warning letter from the U.S. Food and Drug Administration (“FDA”) related to environmental monitoring activities in certain areas of its processing facility in Alachua, Florida. The FDA re-inspected the processing facility in Alachua, Florida in September 2013 and determined that the Company had addressed the FDA’s concerns from the previous inspection. In October 2013, the Company received a final close out letter from the FDA to formally resolve their concerns. The warning letter did not restrict the Company’s ability to process or distribute implants, nor did it require the withdrawal of any implants from the marketplace.

Segment_Data

Segment Data	12 Months Ended
Segment Data	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Data	'
	22. Segment Data
	The Company distributes human tissue, bovine and porcine animal tissue, metal and synthetic implants through various distribution channels. The Company operates in one reportable segment comprised of six lines of business. The Company’s lines of business are comprised primarily of six categories: spine, sports medicine, surgical specialties, BGS and general orthopedic, dental and ortho fixation. Discrete financial information is not available for these six lines of business. The following table presents revenues from these six categories and other revenues and their respective percentages of the Company’s total revenues for the years ended December 31, 2013, 2012 and 2011:


		Year Ended December 31,
		2013					2012				2011
		(In thousands)
	Revenues:
	Spine	$	57,334		28.9	%	$	38,866	21.9	%	$	39,722	23.5	%
	Sports medicine		42,594		21.5	%		51,197	28.7	%		48,122	28.4	%
	Surgical specialties		27,666		14	%		30,897	17.3	%		30,328	17.9	%
	BGS general orthopedic		27,864		14.1	%		29,308	16.5	%		26,291	15.5	%
	Dental		19,779		10	%		21,435	12	%		18,392	10.9	%
	Ortho fixation		14,525		7.3	%		—	—			—	—
	Other revenues		8,217		4.2	%		6,410	3.6	%		6,461	3.8	%

	Total revenues	$	197,979		100	%	$	178,113	100	%	$	169,316	100	%

	Domestic revenues	$	177,207		89.5	%	$	156,803	88	%	$	148,315	87.6	%
	International revenues		20,772		10.5	%		21,310	12	%		21,001	12.4	%

	Total revenues	$	197,979		100	%	$	178,113	100	%	$	169,316	100	%

	The following table presents property, plant and equipment—net by significant geographic location:


		December 31,
		2013		2012
	Property, plant and equipment—net:
	Domestic	$	58,458	$	34,637
	International		16,280		15,007

	Total	$	74,738	$	49,644

Quarterly_Results_of_Operation

Quarterly Results of Operations (Unaudited)	12 Months Ended
Quarterly Results of Operations (Unaudited)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Results of Operations (Unaudited)	'
	23. Quarterly Results of Operations (Unaudited)
	The following table sets forth the results of operations for the periods indicated:


		March 31,		June 30,			September 30,			December 31,
		2013		2013			2013			2013
	Quarter Ended:
	Revenues	$	40,422	$	42,309		$	54,742		$	60,506
	Gross profit		19,196		19,236			20,319			21,354
	Net income (loss) applicable to common shares		1,462		(2,999	)		(9,125	)		(8,527	)
	Net income (loss) per common share:
	Basic	$	0.03	$	(0.05	)	$	(0.16	)	$	(0.15	)
	Diluted		0.03		(0.05	)		(0.16	)		(0.15	)
	In the third quarter of 2013, the Company completed its acquisition of Pioneer which added diversification of our implant portfolio, expanded our direct distribution and marketing organizations and enhanced our international business. Excluding the impact of the Pioneer acquisition, the Company experienced a moderate increase in fees from tissue distribution in its spine and surgical specialties implant categories and decreases in its sports medicine, BGS and general orthopedic and dental implant categories. In addition, sports medicine, BGS and general orthopedic and dental implant categories were negatively impacted by customer uncertainty surrounding our October 2012 FDA warning letter which was resolved in October 2013. In 2013, the Company’s net income was negatively impacted by a litigation settlement charge of $3,000, restructuring charges of $2,881 and acquisition expenses of $6,004.

	The following table sets forth the results of operations for the periods indicated:


		March 31,		June 30,			September 30,			December 31,
		2012		2012			2012			2012
	Quarter Ended:
	Revenues	$	43,743	$	45,197		$	44,566		$	44,607
	Gross profit		20,106		21,671			21,692			21,748
	Net income applicable to common shares		2,002		1,321			2,808			2,271
	Net income per common share:
	Basic	$	0.04	$	0.02		$	0.05		$	0.04
	Diluted		0.04		0.02			0.05			0.04
	During 2012, the Company experienced an increase in fees from tissue distribution in the sports medicine, surgical specialties, BGS and general orthopedic and dental implant categories and a decrease in its spine implant category. Sports medicine, surgical specialties, BGS and general orthopedic, and dental implant categories were positively impacted by increases in unit volumes and increased market penetration through our direct distribution force both domestically and internationally. In addition, the Company experienced a decrease in the other revenues category during 2012. The decrease in the other revenues category was affected by lower tissue recovery fees billed partially offset by higher deferred revenue amortization resulting from exclusivity payments received from our dental and surgical specialties distributors. The Company’s net income was negatively impacted by a litigation settlement charge of $2,350 that was recorded in the second quarter of 2012.

Related_Parties

Related Parties	12 Months Ended
Related Parties	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Parties	'
	24. Related Parties
	From October 2012 through April 2013, the Chairman of the Company’s board of directors was Interim Chief Financial Officer of Stryker Corporation (“Stryker”). Effective May 2013, the Chairman of the Company’s board of directors resumed his previous role as Vice President, Corporate Secretary of Stryker. The Company has a spine distribution agreement, with one year automatic renewals in June, and a BGS and general orthopedic distribution agreement, with two year automatic renewals in May, with Stryker.
	During the years ended December 31, 2013, 2012 and 2011, the Company recognized revenues of $3,043, $6,215 and $5,393, respectively, on distributions to Stryker. Distributions to Stryker for the years ended December 31, 2013, 2012 and 2011 represented 1.5%, 3.5% and 3.2%, respectively, of the Company’s total revenues. Trade accounts receivable due from Stryker totaled $304 and $552 at December 31, 2013 and 2012, respectively.

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	25. Subsequent Events
	The Company evaluated subsequent events as of the issuance date of the consolidated financial statements as defined by FASB ASC 855 Subsequent Events, and identified no subsequent events that require adjustment to, or disclosure of, in these consolidated financial statements.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
Valuation and Qualifying Accounts	Dec. 31, 2013
Valuation And Qualifying Accounts [Abstract]	'
Valuation and Qualifying Accounts	'
	Schedule II
	Valuation and Qualifying Accounts
	Years Ended December 31, 2013, 2012 and 2011
	(Dollars in thousands)


	Description	Balance at		Charged to		Deductions-		Balance at
		Beginning of		Costs and		Write-offs,		End of
		Period		Expenses		Payments		Period
	For the year ended December 31, 2013:
	Allowance for doubtful accounts	$	346	$	180	$	34	$	492
	Allowance for product returns		283		255		195		343
	Allowance for obsolescence		7,735		1,785		4,121		5,399
	Deferred tax asset valuation allowance		469		—		—		469
	For the year ended December 31, 2012:
	Allowance for doubtful accounts		323		54		31		346
	Allowance for product returns		383		82		182		283
	Allowance for obsolescence		8,171		3,114		3,550		7,735
	Deferred tax asset valuation allowance		469		—		—		469
	For the year ended December 31, 2011:
	Allowance for doubtful accounts		190		133		—		323
	Allowance for product returns		300		317		234		383
	Allowance for obsolescence		11,513		4,840		8,182		8,171
	Deferred tax asset valuation allowance		469		—		—		469

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Foreign Currency Translation

Fair Value of Financial Instruments

Presentation of Comprehensive Income (Loss)

Cash and Cash Equivalents

Accounts Receivable Allowances

Inventories

Recalls

Surgical Instruments

Property, Plant and Equipment

Buildings

25 to 40 years

Building improvements and leasehold improvements

8 to 40 years

Processing equipment

7 to 10 years

Office equipment, furniture and fixtures

5 to 7 years

Computer hardware and software

3 years

Surgical instruments

3 years

Software Costs

Software Costs—Included in property, plant and equipment are costs related to purchased software that are capitalized.

Debt Issuance Costs

Long-Lived Assets

Goodwill

•

Change in peer group or performance of peer group companies

•

Change in the Company’s markets and estimates of future operating performance

•

Change in the Company’s estimated market cost of capital

•

Change in implied control premiums related to acquisitions in the medical device industry.

Intangible Assets

Research and Development Costs

Revenue Recognition

Other Revenues

Stock-Based Compensation Plans

Income Taxes

Earnings Per Share

Year Ended December 31,

2013

2012

2011

Basic shares

56,258,624

55,861,957

55,150,886

Effect of dilutive securities:

Stock options

—

206,838

203,789

Diluted shares

56,258,624

56,068,795

55,354,675

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Property, Plant, and Equipment are Stated at Cost Less Accumulated Depreciation

Depreciation is computed on the straight-line method over the following estimated useful lives of the assets:

Buildings

25 to 40 years

Building improvements and leasehold improvements

8 to 40 years

Processing equipment

7 to 10 years

Office equipment, furniture and fixtures

5 to 7 years

Computer hardware and software

3 years

Surgical instruments

3 years

Reconciliation of Common Stock used in Calculation of Basic and Diluted Earnings Per Share

A reconciliation of the number of common shares used in the calculation of basic and diluted EPS is presented below:

Year Ended December 31,

2013

2012

2011

Basic shares

56,258,624

55,861,957

55,150,886

Effect of dilutive securities:

Stock options

—

206,838

203,789

Diluted shares

56,258,624

56,068,795

55,354,675

Merger_with_Pioneer_Surgical_T1

Merger with Pioneer Surgical Technology, Inc. (Tables)	12 Months Ended
Merger with Pioneer Surgical Technology, Inc. (Tables)	Dec. 31, 2013
Business Combinations [Abstract]	'
Summary of Purchase Price	'
	The purchase price was financed as follows:


		(In thousands)
	Cash proceeds from term loan	$	60,000
	Net cash proceeds from preferred share issuance		48,710
	Cash from RTI Surgical		17,597

	Total purchase price	$	126,307

Allocation of the Total Consideration of Tangible and Intangible Assets and Liabilities	'
	The table below represents an allocation of the total consideration to Pioneer’s tangible and intangible assets and liabilities based on management’s preliminary estimate of their respective fair values as of July 16, 2013.


	Inventories	$	35,972
	Accounts receivable		10,567
	Other current assets		6,059
	Property, plant and equipment		15,258
	Other assets		13,260
	Current liabilities		(10,893	)
	Other long-term liabilities		(19,841	)

	Net tangible assets acquired		50,382
	Other intangible assets		23,100
	Goodwill		52,825

	Total net assets acquired	$	126,307

Unaudited Pro Forma Information of the Company's Operations	'
	The following unaudited pro forma information shows the results of the Company’s operations as though the acquisition had occurred as of the beginning of that period (in thousands, except per share data):


		December 31,
		2013			2012
	Revenues	$	243,001		$	266,293
	Net (loss) income applicable to common shares		(5,597	)		4,636
	Basic net (loss) income per share		(0.10	)		0.08
	Diluted net (loss) income per share		(0.10	)		0.08

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Weighted-Average Assumptions Were Used to Determine the Fair Value of Options	'
	The following weighted-average assumptions were used to determine the fair value of options under FASB ASC 718:


		Year Ended December 31,
		2013			2012			2011
	Expected term (years)		6.5			6.5			6.5
	Risk free interest rate		1.3	%		1.38	%		2.72	%
	Volatility factor		47.5	%		64.83	%		66.27	%
	Dividend yield		—			—			—
Stock Options Outstanding, Exercisable and Available for Grant	'
	Stock options outstanding, exercisable and available for grant at December 31, 2013 are summarized as follows:


		Number of			Weighted			Weighted			Aggregate
		Shares			Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price			Contractual
								Life (Years)
	Outstanding at January 1, 2013		5,083,834		$	5.03
	Granted		1,066,500			3.48
	Exercised		(110,590	)		3
	Forfeited or expired		(521,140	)		6.56

	Outstanding at December 31, 2013		5,518,604		$	4.63			5.76		$	1,026

	Vested or expected to vest at December 31, 2013		5,357,211		$	4.66			5.67		$	1,000

	Exercisable at December 31, 2013		3,188,204		$	5.42			4.11		$	542

	Available for grant at December 31, 2013		2,752,053

Stock-Based Compensation Recognized	'
	For the years ended December 31, 2013, 2012 and 2011, the Company recognized stock-based compensation as follows:


		Year Ended December 31,
		2013			2012			2011
	Stock-based compensation:
	Costs of processing and distribution	$	132		$	163		$	207
	Marketing, general and administrative		2,028			1,785			1,705
	Research and development		60			130			61

	Total	$	2,220		$	2,078		$	1,973

Other Information Concerning Stock Options	'
	Other information concerning stock options are as follows:


		Year Ended December 31,
		2013			2012			2011
	Weighted average fair value of stock options granted	$	1.66		$	2.43		$	1.71
	Aggregate intrinsic value of stock options exercised		117			172			926

Inventories_Tables

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Components of Inventories	'
	Inventories by stage of completion are as follows:


		December 31,
		2013		2012
	Unprocessed tissue and raw materials	$	31,468	$	25,962
	Tissue and work in process		39,417		28,379
	Implantable tissue and finished goods		33,102		20,071
	Supplies		2,139		2,097

		$	106,126	$	76,509

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Components of Property, Plant and Equipment	'
	Property, plant and equipment are as follows:


		December 31,
		2013			2012
	Land	$	2,618		$	2,169
	Buildings and improvements		50,106			45,220
	Processing equipment		43,309			31,681
	Surgical instruments		5,012			—
	Office equipment, furniture and fixtures		3,994			2,831
	Computer equipment and software		6,152			5,029
	Construction in process		16,156			7,329
	Equipment under capital leases:
	Processing equipment		396			396
	Computer equipment		744			744
	Office equipment		152			—

			128,639			95,399
	Less accumulated depreciation		(53,901	)		(45,755	)

		$	74,738		$	49,644

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
Goodwill (Tables)	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'

		Year Ended December 31,
		2013		2012
	Balance at January 1	$	2,062	$	—
	Goodwill acquired during the period		52,825		2,062

		$	54,887	$	2,062

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	12 Months Ended
Other Intangible Assets (Tables)	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Components of Other Intangible Assets	'
	Other intangible assets are as follows:


		December 31, 2013				December 31, 2012
		Gross		Accumulated		Gross		Accumulated
		Carrying		Amortization		Carrying		Amortization
		Amount				Amount
	Patents	$	10,637	$	1,935	$	4,616	$	1,443
	Acquired exclusivity rights		2,941		2,787		2,941		2,415
	Acquired licensing rights		10,850		5,326		10,850		4,115
	Marketing and procurement intangible assets		22,098		2,692		4,223		891

	Total	$	46,526	$	12,740	$	22,630	$	8,864

Estimates of Future Amortization Expense	'
	At December 31, 2013, management’s estimates of future amortization expense for the next five years are as follows:


		Amortization
		Expense
	2014	$	4,400
	2015		4,000
	2016		3,400
	2017		3,300
	2018		3,300

		$	18,400

Other_Assets_Tables

Other Assets (Tables)	12 Months Ended
Other Assets (Tables)	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Schedule of Other Assets	'
	Other assets are as follows:


		December 31,
		2013		2012
	Indemnification asset	$	13,000	$	—
	Other		1,332		713

		$	14,332	$	713

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
Accrued Expenses	'
	Accrued expenses are as follows:


		December 31,
		2013		2012
	Accrued compensation	$	3,817	$	6,279
	Accrued donor recovery fees		5,771		3,845
	Accrued restructuring charges		2,609		—
	Accrued distributor commissions		2,059		462
	Accrued taxes		200		3,950
	Contingent consideration		39		900
	Other		7,983		5,158

		$	22,478	$	20,594

Short_and_LongTerm_Obligations1

Short and Long-Term Obligations (Tables)	12 Months Ended
Short and Long-Term Obligations (Tables)	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Short and Long-Term Obligations	'
	Short and long-term obligations are as follows:


		December 31,
		2013			2012
	Term loan	$	60,000		$	—
	Credit facilities		8,911			—
	Capital leases		139			120

	Total		69,050			120
	Less current portion		(1,344	)		(116	)

	Long-term portion	$	67,706		$	4

Contractual Maturities of Short and Long-Term Obligations	'
	As of December 31, 2013, contractual maturities of short and long-term obligations are as follows:


		Term			Credit			Capital		Total
		Loan			Facilities			Leases		Total
	2014	$	625		$	661		$	58	$	1,344
	2015		5,250			—			44		5,294
	2016		4,500			—			32		4,532
	2017		5,250			—			5		5,255
	2018		44,375			8,250			—		52,625

		$	60,000		$	8,911		$	139	$	69,050

Other_LongTerm_Liabilities_Tab

Other Long-Term Liabilities (Tables)	12 Months Ended
Other Long-Term Liabilities (Tables)	Dec. 31, 2013
Text Block [Abstract]	'
Schedule of Other Long-Term Liabilities	'
	Other long-term liabilities are as follows:


		December 31,
		2013		2012
	Indemnification liability	$	13,000	$	—
	Other		446		698

		$	13,446	$	698

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Benefit (Provision)	'
	The Company’s income tax benefit (provision) consists of the following components:


		Year Ended December 31,
		2013			2012			2011
	Current:
	Federal	$	127		$	(1,189	)	$	(842	)
	State		167			(806	)		(925	)
	International		219			(407	)		(2,965	)

	Total current		513			(2,402	)		(4,732	)

	Deferred:
	Federal		8,017			(1,299	)		(20	)
	State		1,675			(181	)		630
	International		905			(160	)		896

	Total deferred		10,597			(1,640	)		1,506

	Total income tax benefit (provision)	$	11,110		$	(4,042	)	$	(3,226	)

Deferred Tax Assets and Liabilities	'
	The components of the deferred tax assets and liabilities consisted of the following at:


		December 31, 2013						December 31, 2012
		Deferred Income Tax						Deferred Income Tax
		Asset			Liability			Asset			Liability
	Current:
	International	$	—		$	(195	)	$	26		$	—
	Allowance for bad debts		400			—			121			—
	Inventory		10,340			—			4,766			—
	Net operating losses		4,040			—			—			—
	Tax credits		1,630			—			1,234			—
	Deferred compensation		3,620			—			3,172			—
	Deferred revenue		2,027			—			1,886			—
	Accrued liabilities		2,643						1,348			—
	Other		—			(123	)		45			—

	Total current		24,700			(318	)		12,598			—

	Noncurrent:
	International		818			—			—			(473	)
	Fixed assets and intangibles		—			(7,615	)		—			(1,565	)
	Investments		2,085			—			2,061			—
	Net operating losses		1,775			—			469			—
	Tax credits		3,768			—			1,961			—
	Deferred revenue		5,066			—			6,195			—
	Accrued liabilities		24			—			—			—
	Valuation allowance		(469	)		—			(469	)		—

	Total noncurrent		13,067			(7,615	)		10,217			(2,038	)

	Total	$	37,767		$	(7,933	)	$	22,815		$	(2,038	)

Unrecognized Tax Benefits	'
	The Company’s unrecognized tax benefits are summarized as follows:


		Year Ended December 31,
		2013			2012			2011
	Opening balance	$	1,797		$	1,674		$	2,341
	(Reductions) additions based on tax positions related to the current year		(174	)		274			154
	Additions for tax positions of prior years		1,337			336			—
	Reductions for tax positions of prior years		(135	)		(487	)		(821	)

		$	2,825		$	1,797		$	1,674

Effective Tax Rate Differs from the Statutory Federal Income Tax Rate	'
	The effective tax rate differs from the statutory federal income tax rate for the following reasons:


		Year Ended December 31,
		2013			2012			2011
	Statutory federal rate		35	%		35	%		35	%
	State income taxes—net of federal tax benefit		4.14	%		5.16	%		1.95	%
	International operations		(0.46	%)		(2.23	%)		—
	Non-deductible expenses		(4.27	%)		—			—
	Research tax credits		3.56	%		(2.06	%)		(3.30	%)
	Domestic production activities deduction		—			(2.29	%)		—
	Unrecognized tax benefits		0.86	%		—			(6.90	%)
	Other reconciling items, net		(0.42	%)		(1.10	%)		1.05	%

	Effective tax rate		38.41	%		32.48	%		27.8	%

Preferred_Stock_Tables

Preferred Stock (Tables)	12 Months Ended
Preferred Stock (Tables)	Dec. 31, 2013
Equity [Abstract]	'
Schedule of Preferred Stock	'
	Preferred stock is as follows:


		December 31,
		2013			2012
	Preferred shares issuance	$	50,000		$	—
	Preferred shares issuance costs		(1,290	)		—

	Net proceeds		48,710			—
	Amortization of preferred shares issuance costs		77			—
	Accrued dividend payable		750			—

		$	49,537		$	—

Restructuring_Charges_Tables

Restructuring Charges (Tables)	12 Months Ended
Restructuring Charges (Tables)	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Schedule of Restructuring Charges	'
	The following table includes a rollforward of restructuring charges included in accrued expenses, see Note 11.


	Accrued restructuring charges at January 1, 2013	$	—
	Employee separation benefits accrued		2,514
	Office closure costs		367

	Subtotal restructuring charges		2,881
	Cash payments		(272	)

	Accrued restructuring charges at December 31, 2013	$	2,609

Concentrations_of_Risk_Tables

Concentrations of Risk (Tables)	12 Months Ended
Concentrations of Risk (Tables)	Dec. 31, 2013
Risks And Uncertainties [Abstract]	'
Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution	'
	The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution:


		Year Ended December 31,
		2013			2012			2011
	Percent of revenues derived from:
	Distributor
	Zimmer, Inc.		17	%		14	%		12	%
	Medtronic, Inc.		16	%		18	%		19	%
	Davol, Inc.		9	%		11	%		11	%
	International		10	%		12	%		12	%

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Future Minimum Lease Commitments under Non-Cancelable Operating Leases	'
	Future minimum lease commitments under non-cancelable operating leases as of December 31, 2013 are as follows:


		Operating
		Leases
	2014	$	1,886
	2015		1,064
	2016		353
	2017		175

		$	3,478

Segment_Data_Tables

Segment Data (Tables)	12 Months Ended
Segment Data (Tables)	Dec. 31, 2013
Segment Reporting [Abstract]	'
Revenues from Tissue Distribution and Other Revenues	'
	The following table presents revenues from these six categories and other revenues and their respective percentages of the Company’s total revenues for the years ended December 31, 2013, 2012 and 2011:


		Year Ended December 31,
		2013					2012				2011
		(In thousands)
	Revenues:
	Spine	$	57,334		28.9	%	$	38,866	21.9	%	$	39,722	23.5	%
	Sports medicine		42,594		21.5	%		51,197	28.7	%		48,122	28.4	%
	Surgical specialties		27,666		14	%		30,897	17.3	%		30,328	17.9	%
	BGS general orthopedic		27,864		14.1	%		29,308	16.5	%		26,291	15.5	%
	Dental		19,779		10	%		21,435	12	%		18,392	10.9	%
	Ortho fixation		14,525		7.3	%		—	—			—	—
	Other revenues		8,217		4.2	%		6,410	3.6	%		6,461	3.8	%

	Total revenues	$	197,979		100	%	$	178,113	100	%	$	169,316	100	%

	Domestic revenues	$	177,207		89.5	%	$	156,803	88	%	$	148,315	87.6	%
	International revenues		20,772		10.5	%		21,310	12	%		21,001	12.4	%

	Total revenues	$	197,979		100	%	$	178,113	100	%	$	169,316	100	%

Schedule of Property, Plant and Equipment - Net by Significant Geographic Location	'
	The following table presents property, plant and equipment—net by significant geographic location:


		December 31,
		2013		2012
	Property, plant and equipment—net:
	Domestic	$	58,458	$	34,637
	International		16,280		15,007

	Total	$	74,738	$	49,644

Quarterly_Results_of_Operation1

Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
Quarterly Results of Operations (Unaudited) (Tables)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Results of Operations	'
	The following table sets forth the results of operations for the periods indicated:


		March 31,		June 30,			September 30,			December 31,
		2013		2013			2013			2013
	Quarter Ended:
	Revenues	$	40,422	$	42,309		$	54,742		$	60,506
	Gross profit		19,196		19,236			20,319			21,354
	Net income (loss) applicable to common shares		1,462		(2,999	)		(9,125	)		(8,527	)
	Net income (loss) per common share:
	Basic	$	0.03	$	(0.05	)	$	(0.16	)	$	(0.15	)
	Diluted		0.03		(0.05	)		(0.16	)		(0.15	)


		March 31,		June 30,			September 30,			December 31,
		2012		2012			2012			2012
	Quarter Ended:
	Revenues	$	43,743	$	45,197		$	44,566		$	44,607
	Gross profit		20,106		21,671			21,692			21,748
	Net income applicable to common shares		2,002		1,321			2,808			2,271
	Net income per common share:
	Basic	$	0.04	$	0.02		$	0.05		$	0.04
	Diluted		0.04		0.02			0.05			0.04

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Recall	Recall	Recall
	Segment
	Assets
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Cash equivalents	$0	$6,667	'
Banks and short-term investments with an original maturity	'Three months or less	'	'
Banks and short-term investments with an original maturity	'3 months	'	'
Cash and cash equivalents include overnight repurchase agreements backed by US Government securities	101.00%	'	'
Cash Equivalent Related to Overnight Repurchase Agreement Percentage of Total Assets	3.00%	'	'
Cash Equivalent Related to Overnight Repurchase Agreement Percentage of Equity	4.00%	'	'
Company number of recall	4	2	2
Number of reporting unit	1	'	'
Identifiable intangible assets	$0	$0	'
Acquired exclusivity rights, remaining amortization period	'8 years	'	'
Number of assets group with intangible assets	1	'	'
Common stock price ranging	$4.63	$5.03	'
Stock Options [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Option purchase	5,518,604	5,083,834	5,636,892
Series A Preferred Stock [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Option purchase	50,000	'	'
Minimum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Common stock price ranging	$2.54	$2.54	1.76
Minimum [Member] \| Patents [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'8 years	'	'
Minimum [Member] \| Trademarks [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'8 years	'	'
Minimum [Member] \| Licensing Rights [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'5 years	'	'
Minimum [Member] \| Customer Lists [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'5 years	'	'
Minimum [Member] \| Non-compete Agreements [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'5 years	'	'
Minimum [Member] \| Distribution Agreement [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'5 years	'	'
Minimum [Member] \| Procurement Contracts [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'5 years	'	'
Maximum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Common stock price ranging	$13.52	$14.95	14.95
Maximum [Member] \| Patents [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'16 years	'	'
Maximum [Member] \| Trademarks [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'16 years	'	'
Maximum [Member] \| Licensing Rights [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'25 years	'	'
Maximum [Member] \| Customer Lists [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'25 years	'	'
Maximum [Member] \| Non-compete Agreements [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'25 years	'	'
Maximum [Member] \| Distribution Agreement [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'25 years	'	'
Maximum [Member] \| Procurement Contracts [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, amortization period	'25 years	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Property, Plant, and Equipment are Stated at Cost Less Accumulated Depreciation (Detail)	12 Months Ended
	Dec. 31, 2013
Computer Hardware and Software [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'3 years
Surgical Instruments [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'3 years
Minimum [Member] \| Building [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'25 years
Minimum [Member] \| Building Improvements and Leasehold Improvements [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'8 years
Minimum [Member] \| Processing Equipment [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'7 years
Minimum [Member] \| Office Equipment, Furniture and Fixtures [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'5 years
Maximum [Member] \| Building [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'40 years
Maximum [Member] \| Building Improvements and Leasehold Improvements [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'40 years
Maximum [Member] \| Processing Equipment [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'10 years
Maximum [Member] \| Office Equipment, Furniture and Fixtures [Member]	'
Depreciation Amortization Impairment [Line Items]	'
Property plant and equipment useful life	'7 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Reconciliation of Common Stock Used in Calculation of Basic and Diluted Earnings Per Share (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Basic shares	56,258,624	55,861,957	55,150,886
Effect of dilutive securities	'	'	'
Stock options	'	206,838	203,789
Diluted shares	56,258,624	56,068,795	55,354,675

Merger_with_Pioneer_Surgical_T2

Merger with Pioneer Surgical Technology, Inc. - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Jul. 17, 2013

Dec. 31, 2012

Jul. 17, 2013

Dec. 31, 2013

Pioneer [Member]

Operating Segments [Member]

Senior Secured Facility [Member]

Bank Term Loan [Member]

Revolving Credit Facility [Member]

Convertible Preferred Stock [Member]

Minimum [Member]

Maximum [Member]

Senior Secured Facility [Member]

Business Acquisition [Line Items]

Business acquisition agreement date

12-Jun-13

Business acquisition cash consideration

$126,307

Business acquisition date

16-Jul-13

Term of senior secured credit facility

'5 years

Amount of senior secured facility obtained

80,000

60,000

20,000

Maturity date of senior secured credit facility

16-Jul-18

Variable interest rate, basis point

1.00%

3.00%

Existing credit facility amount replaced by new revolving credit facility

15,000

Proceeds from issuance of convertible preferred stock

50,000

Convertible preferred stock dividend rate

6.00%

Financing cost and expense

1,989

Acquisition costs expense

6,004

Goodwill assigned to operating segment

54,887

52,825

2,062

52,825

Fair value of receivables

10,567

Contractual amount, gross

11,712

Uncollected amount

1,145

Revenue

35,994

Net income

$894

Merger_with_Pioneer_Surgical_T3

Merger with Pioneer Surgical Technology, Inc. - Summary of Purchase Price (Detail) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Jul. 17, 2013
Business Combinations [Abstract]	'
Cash proceeds from term loan	$60,000
Net cash proceeds from preferred share issuance	48,710
Cash from RTI Surgical	17,597
Total purchase price	$126,307

Merger_with_Pioneer_Surgical_T4

Merger with Pioneer Surgical Technology, Inc. - Allocation of the Total Consideration of Tangible and Intangible Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Jul. 17, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Jul. 17, 2013	Dec. 31, 2012
Business Combinations [Abstract]	'	'	'
Inventories	'	$35,972	'
Accounts receivable	'	10,567	'
Other current assets	'	6,059	'
Property, plant and equipment	'	15,258	'
Other assets	'	13,260	'
Current liabilities	'	-10,893	'
Other long-term liabilities	'	-19,841	'
Net tangible assets acquired	'	50,382	'
Other intangible assets	'	23,100	'
Goodwill	54,887	52,825	2,062
Total net assets acquired	'	$126,307	'

Merger_with_Pioneer_Surgical_T5

Merger with Pioneer Surgical Technology, Inc. - Unaudited Pro Forma Information of the Company's Operations (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Business Combinations [Abstract]	'	'
Revenues	$243,001	$266,293
Net (loss) income applicable to common shares	($5,597)	$4,636
Basic net (loss) income per share	($0.10)	$0.08
Diluted net (loss) income per share	($0.10)	$0.08

Acquisition_of_Recovery_Group_

Acquisition of Recovery Group - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Jul. 17, 2013	Dec. 28, 2012	Dec. 31, 2013
	Dec. 31, 2012	Jul. 17, 2013	Recovery [Member]	Recovery [Member]
Business Acquisition [Line Items]	'	'	'	'
Business acquisition maximum purchase price	'	$126,307	$3,900	'
Payment for acquisition of business	3,000	'	3,000	861
Purchase price consideration, additional payment	'	'	$900	'
Contingent payment is recorded in accrued expenses	'	'	'	'30 days

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Plans	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Contractual terms of stock options granted, in years	'10 years	'	'
Stock-based compensation plans, number	5	'	'
Percentage of market value of common stock, stock options exercise price	100.00%	'	'
Percentage of market value of common stock, restricted stock award granted	100.00%	'	'
Dividend yield	0.00%	'	'
Income tax benefits	($11,110)	$4,042	$3,226
Restricted Stock Awards [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total unrecognized stock-based compensation	765	'	'
Weighted-average period recognized stock-based compensation	'1 year 1 month 17 days	'	'
Restricted stock granted during period	290,579	'	'
Weighted-average grant date fair value of restricted stock granted	$3.71	'	'
Restricted Stock Awards [Member] \| Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation award, vesting period	'1 year	'	'
Restricted Stock Awards [Member] \| Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation award, vesting period	'3 years	'	'
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Dividend yield	'	'	'
Outstanding option, expiry period	'10 years	'	'
Total unrecognized stock-based compensation	3,260	'	'
Weighted-average period recognized stock-based compensation	'3 years 1 month 17 days	'	'
Income tax benefits	$883	$801	$660
Stock Options [Member] \| Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation award, vesting period	'1 year	'	'
Stock Options [Member] \| Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation award, vesting period	'5 years	'	'
1998 Stock Option Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares of common stock to be issued with respect to awards granted	4,406,400	'	'
2004 Equity Incentive Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares of common stock to be issued with respect to awards granted	2,000,000	'	'
2010 Equity Incentive Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares of common stock to be issued with respect to awards granted	5,000,000	'	'
TMI 1996 Stock Option Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares of common stock to be issued with respect to awards granted	4,880,000	'	'
TMI 2006 Incentive and Non Statutory Stock Option Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares of common stock to be issued with respect to awards granted	1,830,000	'	'

StockBased_Compensation_Weight

Stock-Based Compensation - Weighted-Average Assumptions were Used to Determine the Fair Value of Options (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Dividend yield	0.00%	'	'
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected term (years)	'6 years 6 months	'6 years 6 months	'6 years 6 months
Risk free interest rate	1.30%	1.38%	2.72%
Volatility factor	47.50%	64.83%	66.27%
Dividend yield	'	'	'

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Options Outstanding, Exercisable and Available for Grant (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Outstanding, Number of Shares	5,083,834
Granted, Number of Shares	1,066,500
Exercised, Number of Shares	-110,590
Forfeited or expired, Number of Shares	-521,140
Outstanding, Number of Shares	5,518,604
Vested or expected to vest, Number of Shares	5,357,211
Exercisable, Number of Shares	3,188,204
Available for grant, Number of Shares	2,752,053
Outstanding, Weighted Average Exercise Price	$5.03
Granted, Weighted Average Exercise Price	$3.48
Exercised, Weighted Average Exercise Price	$3
Forfeited or expired, Weighted Average Exercise Price	$6.56
Outstanding, Weighted Average Exercise Price	$4.63
Vested or expected to vest, Weighted Average Exercise Price	$4.66
Exercisable, Weighted Average Exercise Price	$5.42
Outstanding, Weighted Average Remaining Contractual Life (Years)	'5 years 9 months 4 days
Vested or expected to vest, Weighted Average Remaining Contractual Life (Years)	'5 years 8 months 1 day
Exercisable, Weighted Average Remaining Contractual Life (Years)	'4 years 1 month 10 days
Outstanding, Aggregate Intrinsic Value	$1,026
Vested or expected to vest, Aggregate Intrinsic Value	1,000
Exercisable, Aggregate Intrinsic Value	$542

StockBased_Compensation_StockB

Stock-Based Compensation - Stock-Based Compensation Recognized (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation	$2,220	$2,078	$1,973
Costs of Processing and Distribution [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation	132	163	207
Marketing, General and Administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation	2,028	1,785	1,705
Research and Development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation	$60	$130	$61

StockBased_Compensation_Other_

Stock-Based Compensation - Other Information Concerning Stock Options (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Weighted average fair value of stock options granted	$1.66	$2.43	$1.71
Aggregate intrinsic value of stock options exercised	$117	$172	$926

Inventories_Components_of_Inve

Inventories - Components of Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]	'	'
Unprocessed tissue and raw materials	$31,468	$25,962
Tissue and work in process	39,417	28,379
Implantable tissue and finished goods	33,102	20,071
Supplies	2,139	2,097
Inventory - net	$106,126	$76,509

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Inventory Disclosure [Abstract]	'	'	'
Inventory write-downs	$1,785	$3,114	$4,840
Inventory purchase price adjustment amount	$5,708	'	'

Property_Plant_and_Equipment_C

Property, Plant and Equipment - Components of Property, Plant and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Land	$2,618	$2,169
Buildings and improvements	50,106	45,220
Processing equipment	43,309	31,681
Surgical instruments	5,012	'
Office equipment, furniture and fixtures	3,994	2,831
Computer equipment and software	6,152	5,029
Construction in process	16,156	7,329
Property, plant and equipment, gross	128,639	95,399
Less accumulated depreciation	-53,901	-45,755
Total	74,738	49,644
Processing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment under capital leases	396	396
Computer Hardware and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment under capital leases	744	744
Office Equipment, Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Office equipment	$152	'

PropertyPlant_and_Equipment_Ad

Property,Plant and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property Plant And Equipment [Abstract]	'	'	'
Depreciation expense of property, plant and equipment	$8,267	$5,970	$6,039

Goodwill_Goodwill_Detail

Goodwill - Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Jul. 17, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'
Beginning Balance, Goodwill	$2,062	'	$52,825
Goodwill acquired during the year	52,825	2,062	'
Ending Balance, Goodwill	$54,887	$2,062	$52,825

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Jul. 17, 2013	Dec. 31, 2012
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'
Goodwill assigned to operating segment	$54,887	$52,825	$2,062
Goodwill impairment loss	$0	'	'

Other_Intangible_Assets_Compon

Other Intangible Assets - Components of Other Intangible Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$46,526	$22,630
Accumulated Amortization	12,740	8,864
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	10,637	4,616
Accumulated Amortization	1,935	1,443
Acquired Exclusivity Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	2,941	2,941
Accumulated Amortization	2,787	2,415
Licensing Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	10,850	10,850
Accumulated Amortization	5,326	4,115
Other [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	22,098	4,223
Accumulated Amortization	$2,692	$891

Other_Intangible_Assets_Additi

Other Intangible Assets - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jul. 17, 2013

Dec. 28, 2012

Jul. 17, 2013

Dec. 31, 2013

Sep. 10, 2010

Dec. 31, 2013

Jul. 17, 2014

Dec. 31, 2013

Jul. 17, 2013

Dec. 31, 2013

Jul. 17, 2013

Dec. 31, 2013

Jul. 17, 2013

Dec. 31, 2013

Jul. 17, 2013

Third Party Donor Recovery Agency [Member]

Pioneer [Member]

Athersys License Agreement [Member]

Non-compete Agreements [Member]

Patents [Member]

Distribution Agreement [Member]

Installment

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Third Party Donor Recovery Agency [Member]

Pioneer [Member]

Finite-Lived Intangible Assets [Line Items]

Amount of Intangible assets acquired

$23,100

Intangible assets, estimated useful life for amortization

'5 years

'25 years

'8 years

'5 years

'16 years

'12 years

'5 years

'25 years

'12 years

Weighted average term of the patents and distribution agreements

'10 years 6 months

'9 years 2 months 12 days

Amount of Intangible assets acquired

1,838

Estimated useful life

'8 years

'5 years

'20 years

Non-refundable license fee

3,000

Number of installments for non-refundable license fee amount

Three time-based installments for non-refundable license fee, amount

1,000

Contingent payment

2,000

Achievement of certain cumulative revenue

32,500

License agreement covered

'5 years

Amortization expense of other intangible assets

$3,935

$2,023

$1,987

Other_Intangible_Assets_Estima

Other Intangible Assets - Estimates of Future Amortization Expense (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
2014	$4,400
2015	4,000
2016	3,400
2017	3,300
2018	3,300
Total future amortization expense	$18,400

Other_Assets_Schedule_of_Other

Other Assets - Schedule of Other Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Indemnification asset	$13,000	'
Other	1,332	713
Total other assets	$14,332	$713

Other_Assets_Additional_Inform

Other Assets - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'	'
Indemnification asset	$13,000	'	'
Deposited in escrow account	13,000	'	'
Indemnification liability	13,000	'	'
Interest expense associated with the amortization of debt issuance costs	$57	$23	$22

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Payables And Accruals [Abstract]	'	'
Accrued compensation	$3,817	$6,279
Accrued donor recovery fees	5,771	3,845
Accrued restructuring charges	2,609	'
Accrued distributor commissions	2,059	462
Accrued taxes	200	3,950
Contingent consideration	39	900
Other	7,983	5,158
Total accrued expenses	$22,478	$20,594

Short_and_LongTerm_Obligations2

Short and Long-Term Obligations - Short and Long-Term Obligations (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]	'	'
Term loan	$60,000	'
Credit facilities	8,911	'
Capital leases	139	120
Total	69,050	120
Less current portion	-1,344	-116
Long-term portion	$67,706	$4

Short_and_LongTerm_Obligations3

Short and Long-Term Obligations - Additional Information (Detail)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Jul. 17, 2013

Dec. 31, 2013

Jul. 17, 2013

Dec. 31, 2013

USD ($)

Credit Facilities [Member]

Capital Leases [Member]

TD Bank and Regions Bank [Member]

German Banks [Member]

USD ($)

Senior Secured Facility [Member]

Bank Term Loan [Member]

Revolving Credit Facility [Member]

Minimum [Member]

Maximum [Member]

USD ($)

EUR (€)

Revolving Credit Facility [Member]

Credit Facilities [Member]

Secured by Mortgage [Member]

Secured by Accounts Receivable [Member]

Debt_Instruments

USD ($)

Senior Secured Facility [Member]

USD ($)

Debt_Instruments

EUR (€)

Standby Letters of Credit [Line Items]

Term of senior secured credit facility

'5 years

Amount of senior secured facility obtained

$80,000

$60,000

$20,000

Maturity date of senior secured credit facility

16-Jul-18

Variable interest rate, basis point

1.00%

3.00%

Existing credit facility amount replaced by new revolving credit facility

15,000

Variable interest rate base

'One month LIBOR rate

Revolving credit facility variable interest rate

2.42%

Minimum cash balance required for covenant compliance

10,000

Covenant Terms of Credit Facility

'The new credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, payments of dividends, require a minimum cash balance on hand of $10,000, and require certain financial covenant ratios.

Long-term obligations outstanding, number

Credit facility, current borrowing capacity

13,436

Credit outstanding

8,911

8,250

661

Credit facility, borrowing capacity

2,340

1,700

Credit facility, secured

1,000

500

Credit facility, unsecured amount

200

Minimum interest rates

1.49%

3.30%

Maximum interest rates

8.46%

6.00%

Capital leases maturity date

'2017

Future maturities of capital leases

69,050

139

Interest included in minimum lease payments

Present value of minimum lease payments

$136

Short_and_LongTerm_Contractual

Short and Long-Term - Contractual Maturities of Short and Long-Term Obligations (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Schedule Of Short Term And Long Term Debt [Line Items]	'
2014	$1,344
2015	5,294
2016	4,532
2017	5,255
2018	52,625
Capital leases, total	69,050
Term Loan [Member]	'
Schedule Of Short Term And Long Term Debt [Line Items]	'
2014	625
2015	5,250
2016	4,500
2017	5,250
2018	44,375
Capital leases, total	60,000
Credit Facilities [Member]	'
Schedule Of Short Term And Long Term Debt [Line Items]	'
2014	661
2015	'
2016	'
2017	'
2018	8,250
Capital leases, total	8,911
Capital Leases [Member]	'
Schedule Of Short Term And Long Term Debt [Line Items]	'
2014	58
2015	44
2016	32
2017	5
2018	'
Capital leases, total	$139

Other_LongTerm_Liabilities_Sch

Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Other Liabilities Disclosure [Abstract]	'	'
Indemnification liability	$13,000	'
Other	446	698
Total other long-term liabilities	$13,446	$698

Other_LongTerm_Liabilities_Add

Other Long-Term Liabilities - Additional Information (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
Indemnification liability	$13,000

Income_Taxes_Income_Tax_Benefi

Income Taxes - Income Tax Benefit (Provision) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	$127	($1,189)	($842)
State	167	-806	-925
International	219	-407	-2,965
Total current	513	-2,402	-4,732
Deferred:	'	'	'
Federal	8,017	-1,299	-20
State	1,675	-181	630
International	905	-160	896
Total deferred	10,597	-1,640	1,506
Total income tax benefit (provision)	$11,110	($4,042)	($3,226)

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current:	'	'
Deferred income tax asset, international	'	$26
Deferred income tax asset, allowance for bad debts	400	121
Deferred income tax asset, inventory	10,340	4,766
Deferred income tax asset, net operating losses	4,040	'
Deferred income tax asset, tax credits	1,630	1,234
Deferred income tax asset, deferred compensation	3,620	3,172
Deferred income tax asset, deferred revenue	2,027	1,886
Deferred income tax asset, accrued liabilities	2,643	1,348
Deferred income tax asset, other	'	45
Deferred income tax asset, total current	24,700	12,598
Noncurrent:	'	'
Deferred income tax asset, international	818	'
Deferred income tax asset, fixed assets and intangibles	'	'
Deferred income tax asset, investments	2,085	2,061
Deferred income tax asset, net operating losses	1,775	469
Deferred income tax asset, tax credits	3,768	1,961
Deferred income tax asset, deferred revenue	5,066	6,195
Deferred income tax asset, accrued liabilities	24	'
Deferred income tax asset, valuation allowance	-469	-469
Deferred income tax asset, total noncurrent	13,067	10,217
Deferred income tax asset, total	37,767	22,815
Current:	'	'
Deferred income tax liability, international	-195	'
Deferred income tax liability, allowance for bad debts	'	'
Deferred income tax liability, inventory	'	'
Deferred income tax liability, net operating losses	'	'
Deferred income tax liability, tax credits	'	'
Deferred income tax liability, deferred compensation	'	'
Deferred income tax liability, deferred revenue	'	'
Deferred income tax liability, accrued liabilities	'	'
Deferred income tax liability, other	-123	'
Deferred income tax liability, total current	-318	'
Noncurrent:	'	'
Deferred income tax liability, international	'	-473
Deferred income tax liability, fixed assets and intangibles	-7,615	-1,565
Deferred income tax liability, investments	'	'
Deferred income tax liability, net operating losses	'	'
Deferred income tax liability, tax credits	'	'
Deferred income tax liability, deferred revenue	'	'
Deferred income tax liability, accrued liabilities	'	'
Deferred income tax liability, valuation allowance	'	'
Deferred income tax liability, total noncurrent	-7,615	-2,038
Deferred income tax liability, total	($7,933)	($2,038)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Operating Loss Carryforwards [Line Items]	'	'	'	'
Deferred tax assets	$29,834	'	'	'
Domestic deferred tax assets, valuation allowances	469	469	'	'
Tax benefit from the exercise of stock options	315	1,107	313	'
Net operating loss carryforwards	20,169	'	'	'
State net operating loss carryforwards expiration period, start year	'2017	'	'	'
State net operating loss carryforwards expiration period, end year	'2033	'	'	'
Research tax credit carryforwards	6,677	'	'	'
Research tax credit carry forwards expiration period, minimum in years	'2025	'	'	'
Research tax credit carryforwards expiration period, maximum in years	'2033	'	'	'
Alternative minimum tax credit carry forwards	827	'	'	'
Undistributed earnings of foreign subsidiaries	7,365	10,364	'	'
Unrecognized tax benefits	2,825	1,797	1,674	2,341
Other liabilities	720	'	'	'
Unrecognized tax benefits were recorded net against deferred tax assets	2,105	'	'	'
Percentage of utilization of deferred tax assets before expiration	100.00%	'	'	'
Primary measure of cumulative losses number of rolling years	'3 years	'	'	'
Unrecognized tax benefits will decrease and be recognized in 2013 the next twelve months	895	'	'	'
Interest and penalties recorded	0	0	0	'
Interest and penalties accrued	0	0	'	'
Significant other reconciling items	$0	$0	$0	'
Domestic Tax Authority [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Income tax examination period	'2010	'	'	'
Minimum [Member] \| Foreign Tax Authority [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Income tax examination period	'2006	'	'	'
Maximum [Member] \| Foreign Tax Authority [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Income tax examination period	'2009	'	'	'

Income_Taxes_Unrecognized_Tax_

Income Taxes - Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Opening balance	$1,797	$1,674	$2,341
(Reductions) additions based on tax positions related to the current year	-174	274	154
Additions for tax positions of prior years	1,337	336	'
Reductions for tax positions of prior years	-135	-487	-821
Closing balance	$2,825	$1,797	$1,674

Income_Taxes_Effective_Tax_Rat

Income Taxes - Effective Tax Rate Differs from the Statutory Federal Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Statutory federal rate	35.00%	35.00%	35.00%
State income taxes-net of federal tax benefit	4.14%	5.16%	1.95%
International operations	-0.46%	-2.23%	'
Non-deductible expenses	-4.27%	'	'
Research tax credits	3.56%	-2.06%	-3.30%
Domestic production activities deduction	'	-2.29%	'
Unrecognized tax benefits	0.86%	'	-6.90%
Other reconciling items, net	-0.42%	-1.10%	1.05%
Effective tax rate	38.41%	32.48%	27.80%

Preferred_Stock_Schedule_of_Pr

Preferred Stock - Schedule of Preferred Stock (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Temporary Equity [Line Items]	'	'
Preferred shares issuance	$49,537	'
Preferred shares issuance costs	-1,290	'
Net proceeds	48,710	'
Amortization of preferred shares issuance costs	77	'
Accrued dividend payable	750	'
Total	49,537	'
Series A Preferred Stock [Member]	'	'
Temporary Equity [Line Items]	'	'
Preferred shares issuance	50,000	'
Amortization of preferred shares issuance costs	$77	'

Preferred_Stock_Additional_Inf

Preferred Stock - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Jul. 15, 2013	Jun. 12, 2013	Jul. 15, 2013
In Thousands, except Per Share data, unless otherwise specified		Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Private Placement with WSHP [Member]	Private Placement with WSHP [Member]	Private Placement with WSHP [Member]
				Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]
						Minimum [Member]
Temporary Equity [Line Items]	'	'	'	'	'	'
Private placement of convertible preferred equity	$49,537	$50,000	'	'	$50,000	'
Convertible preferred stock, par value	$0.00	'	'	$0.00	'	'
Preferred stock dividend rate	'	'	'	6.00%	'	'
Preferred stock conversion price, per share	'	'	'	$4.39	'	'
Convertible preferred stock number of shares to be issued for each share of preferred stock upon approval	'	'	'	$228	'	'
Closing price of share	'	'	'	$7.98	'	'
Convertible preferred stock description of Conversion	'	'	'	'The Preferred Stock is convertible at the election of the Company five years after its issuance or at any time if the Company's common stock closes at or above $7.98 per share for at least 20 consecutive trading days.	'	'
Consecutive trading days	'	'	'	'	'	'20 days
Preferred stock conversion after issuance, period	'	'	'	'5 years	'	'
Liquidation value	'	'	'	$1,000	'	'
Convertible preferred stock description of Conversion Two	'	'	'	'The Company may, upon 30 days notice, redeem the Preferred Stock, in whole or in part, five years after its issuance at the liquidation value of $1,000 per share of the Preferred Stock plus an amount per share equal to accrued but unpaid dividends (collectively, the bLiquidation Valueb). The holders of the Preferred Stock may require the Company to redeem their Preferred Stock, in whole or in part, at the Liquidation Value seven years after its issuance or upon the occurrence of a change of control.	'	'
Preferred stock conversion after issuance, period Two	'	'	'	'7 years	'	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	Vote	Dec. 31, 2012
Equity [Abstract]	'	'
Preferred stock, shares authorized	5,000,000	'
Preferred stock, shares issued	50,000	'
Preferred stock, shares outstanding	50,000	'
Common stock, shares authorized	150,000,000	150,000,000
Number of votes per common share	1	'

Restructuring_Charges_Addition

Restructuring Charges - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]	'
Acquisition expenses	$2,881
Minimum [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Severance payment period	'1 month
Maximum [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Severance payment period	'12 months

Restructuring_Charges_Schedule

Restructuring Charges - Schedule of Restructuring Charges (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Accrued restructuring charges, beginning balance	'
Employee separation benefits accrued	2,514
Office closure costs	367
Subtotal restructuring charges	2,881
Cash payments	-272
Accrued restructuring charges, ending balance	$2,609

Retirement_Benefits_Additional

Retirement Benefits - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Cost recognized under retirement benefit plan	$1,964	$1,501	$1,359
Maximum [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Retirement benefits, employer's contribution percentage	6.00%	'	'

Concentrations_of_Risk_Additio

Concentrations of Risk - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Companies
Risks And Uncertainties [Abstract]	'
Revenue distribution of number of companies	14
Revenue from number of companies	3

Concentrations_of_Risk_Schedul

Concentrations of Risk - Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution (Detail) (Sales [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Zimmer, Inc. [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of revenues	17.00%	14.00%	12.00%
Medtronic, Inc. [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of revenues	16.00%	18.00%	19.00%
Davol, Inc. [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of revenues	9.00%	11.00%	11.00%
International Customers [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of revenues	10.00%	12.00%	12.00%

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended				3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 12, 2013	Sep. 10, 2010	Sep. 30, 2010	Jul. 13, 2009	Mar. 31, 2013	Dec. 31, 2010	Dec. 31, 2013
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Medtronic, Inc. [Member]	Athersys, Inc. [Member]	Zimmer, Inc. [Member]	Davol, Inc. [Member]	Davol, Inc. [Member]	Davol, Inc. [Member]	Davol, Inc. [Member]
Commitment And Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Decline in cumulative fees received, trailing period	'	'	'	'12 months	'	'	'	'	'	'
Distribution agreement automatic renewal term	'	'	'	'5 years	'	'	'	'	'	'
Period prior to expiration of initial term for notice	'	'	'	'1 year	'	'	'	'	'	'
Agreement expiry date	'	'	'	30-Jun-14	'	'	'	'	'	'
Non-refundable license fee	'	'	'	'	$3,000	'	$8,000	'	'	'
License fee payable in three time-based installments	'	'	'	'	1,000	'	'	'	'	'
Payment contingent upon successful achievement of certain development milestones	'	'	'	'	2,000	'	'	'	'	'
Payment contingent upon achievement of certain cumulative revenue milestones	'	'	'	'	32,500	'	'	'	'	'
Exclusive license agreement period maximum	'	'	'	'	'5 years	'	'	'	'	'
Agreement initial term years	'	'	'	'	'	'10 years	'	'	'	'10 years
Upfront payment	'	'	'	'	'	13,000	'	'	'	'
Upfront payment period	'	'	'	'	'	'10 days	'	'	'	'
Revenue milestone payment	'	'	'	'	'	'	'	'	3,500	'
Exclusivity payments	3,500	'	'	'	'	'	'	'	'	8,000
Exclusive worldwide distribution agreement extended expiration date	'	'	'	'	'	'	'	'	'	13-Jul-19
Deferred revenue recognition	6,000	3,000	'	'	'	'	'	1,715	'	'
Rent expense	$1,529	$1,302	$1,041	'	'	'	'	'	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Lease Commitments under Non-Cancelable Operating Leases (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
2014	$1,886
2015	1,064
2016	353
2017	175
Total	$3,478

Legal_and_Regulatory_Actions_A

Legal and Regulatory Actions - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Jul. 25, 2013	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2013	Dec. 31, 2012
					Litigation	Lawsuits
					Lawsuits
Commitments And Contingencies Disclosure [Abstract]	'	'	'	'	'	'
Outstanding claims	'	'	'	'	0	'
Number of lawsuits settled by agreement on financial terms	'	'	'	'	'	29
Litigation settlement charge	'	$3,000	$2,350	$2,350	$3,000	'
Answerable indemnity insurance	'	'	'	'	2,000	'
Contingent interest payable	300	'	'	'	'	'
Contingent interest receivable	'	'	'	'	300	'
Upfront payment of contingent interest	$2,700	'	'	'	'	'

Segment_Data_Additional_Inform

Segment Data - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Segment
Segment Reporting [Abstract]	'
Number of reportable segments	1
Number of business lines	6

Segment_Data_Revenues_from_Tis

Segment Data - Revenues from Tissue Distribution and Other Revenues (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Other revenues	'	'	'	'	'	'	'	'	$8,217	$6,410	$6,461
Total revenues	60,506	54,742	42,309	40,422	44,607	44,566	45,197	43,743	197,979	178,113	169,316
Percentage of other revenues	'	'	'	'	'	'	'	'	4.20%	3.60%	3.80%
Percentage of revenues	'	'	'	'	'	'	'	'	100.00%	100.00%	100.00%
Domestic [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	177,207	156,803	148,315
Percentage of domestic revenues	'	'	'	'	'	'	'	'	89.50%	88.00%	87.60%
International [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	20,772	21,310	21,001
Percentage of international revenues	'	'	'	'	'	'	'	'	10.50%	12.00%	12.40%
Spine [Member] \| Tissue Distribution [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Tissue distribution	'	'	'	'	'	'	'	'	57,334	38,866	39,722
Percentage of sales revenue	'	'	'	'	'	'	'	'	28.90%	21.90%	23.50%
Sports Medicine [Member] \| Tissue Distribution [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Tissue distribution	'	'	'	'	'	'	'	'	42,594	51,197	48,122
Percentage of sales revenue	'	'	'	'	'	'	'	'	21.50%	28.70%	28.40%
Surgical Specialties [Member] \| Tissue Distribution [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Tissue distribution	'	'	'	'	'	'	'	'	27,666	30,897	30,328
Percentage of sales revenue	'	'	'	'	'	'	'	'	14.00%	17.30%	17.90%
BGS and General Orthopedic [Member] \| Tissue Distribution [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Tissue distribution	'	'	'	'	'	'	'	'	27,864	29,308	26,291
Percentage of sales revenue	'	'	'	'	'	'	'	'	14.10%	16.50%	15.50%
Dental [Member] \| Tissue Distribution [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Tissue distribution	'	'	'	'	'	'	'	'	19,779	21,435	18,392
Percentage of sales revenue	'	'	'	'	'	'	'	'	10.00%	12.00%	10.90%
Ortho Fixation [Member] \| Tissue Distribution [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Tissue distribution	'	'	'	'	'	'	'	'	$14,525	'	'
Percentage of sales revenue	'	'	'	'	'	'	'	'	7.30%	'	'

Segment_Data_Schedule_of_Prope

Segment Data - Schedule of Property, Plant and Equipment - Net by Significant Geographic Location (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment-net	$74,738	$49,644
Domestic [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment-net	58,458	34,637
International [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment-net	$16,280	$15,007

Quarterly_Results_of_Operation2

Quarterly Results of Operations (Unaudited) - Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$60,506	$54,742	$42,309	$40,422	$44,607	$44,566	$45,197	$43,743	$197,979	$178,113	$169,316
Gross profit	21,354	20,319	19,236	19,196	21,748	21,692	21,671	20,106	80,105	85,217	77,214
Net income (loss) applicable to common shares	($8,527)	($9,125)	($2,999)	$1,462	$2,271	$2,808	$1,321	$2,002	($17,814)	$8,402	$8,378
Net income (loss) per common share	'	'	'	'	'	'	'	'	'	'	'
Basic	($0.15)	($0.16)	($0.05)	$0.03	$0.04	$0.05	$0.02	$0.04	($0.34)	$0.15	$0.15
Diluted	($0.15)	($0.16)	($0.05)	$0.03	$0.04	$0.05	$0.02	$0.04	($0.34)	$0.15	$0.15

Quarterly_Results_of_Operation3

Quarterly Results of Operations (Unaudited) - Additional Information (Detail) (USD $)	3 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'
Litigation settlement charge	$3,000	$2,350	$2,350	$3,000
Restructuring charges	'	'	'	2,881
Acquisition expenses	'	'	'	$6,004

Related_Parties_Additional_Inf

Related Parties - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Party Transactions [Abstract]	'	'	'
Distribution agreements with renewal description	'The Company has a spine distribution agreement, with one year automatic renewals in June, and a BGS and general orthopedic distribution agreement, with two year automatic renewals in May, with Stryker.	'	'
Revenue from related parties	$3,043	$6,215	$5,393
Percentage of company's total revenues	1.50%	3.50%	3.20%
Trade accounts receivable due from Stryker	$304	$552	'

Schedule_II_Valuation_and_Qual

Schedule II Valuation and Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
	Allowance for Doubtful Accounts [Member]	Allowance for Doubtful Accounts [Member]	Allowance for Doubtful Accounts [Member]	Allowance for Product Returns [Member]	Allowance for Product Returns [Member]	Allowance for Product Returns [Member]	Allowance for Obsolescence [Member]	Allowance for Obsolescence [Member]	Allowance for Obsolescence [Member]	Deferred Tax Asset Valuation Allowance [Member]	Deferred Tax Asset Valuation Allowance [Member]	Deferred Tax Asset Valuation Allowance [Member]	Deferred Tax Asset Valuation Allowance [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'
Balance at Beginning of Period	$346	$323	$190	$283	$383	$300	$7,735	$8,171	$11,513	$469	$469	$469	$469
Charged to Costs and Expenses	180	54	133	255	82	317	1,785	3,114	4,840	'	'	'	'
Deductions- Write-offs, Payments	34	31	'	195	182	234	4,121	3,550	8,182	'	'	'	'
Balance at End of Period	$492	$346	$323	$343	$283	$383	$5,399	$7,735	$8,171	$469	$469	$469	$469